Cli nical pr ot oc ol:  
Title:  A M ulti - Ce nter, O pe n La bel, T O F U E xte nsi o n St u d y Assessi n g t he Efficac y a n d Saf et y of 
A d diti o nal I ntr a vitreal I njecti o ns of R B M - 0 0 7 i n S u bjects wit h Wet A ge-r elate d Mac ul ar De ge nerati o n – R A M E N St u d y 
N C T 0 4 6 4 0 2 7 2 
Date: [ADDRESS_143589] a bl e S ol uti o n 
 Pr ot oc ol R B M -0 0 7 -0 0 3   
1 of  7 4    
 
R B M R B M - -0 0 7 0 0 7   
Pr ot oc ol Pr ot oc ol   R B M 0 0 7 R B M 0 0 7 - -0 0 3 0 0 3   
  
TI T L E: A M ulti - C e nt er, O p e n L a b el, T O F U E xt e n si o n St u d y A s s e s si n g t h e Effic ac y 
a n d S af et y of A d diti o n al I ntr a vitr e al I nj ecti o n s of  R R B M B M - -[ADDRESS_143590] s w it h Wet 
A g e -r el at e d M M ac ul ar D ac ul ar D e e g e n er ati o g e n er ati o n n  – RA M E N  St u d y   
 
 
S P O N S O R : 
RI B O MI C U S A I nc.  
[ADDRESS_143591].  Ber kele y, C A 9 4 7 0 4 S T U D Y D R U G:  
2. 0 m g ( 1 0 0 µ L of 2 0 m g/ m L) R B M - [ADDRESS_143592] u d y u ntil I h a v e o bt ai n e d writt e n a p pr o v al b y t h e 
a p pr o pri at e I n stit uti o n al R e vi e w B o ar d (I R B) or Et hic s C o m mitt e e ( E C) a n d h a v e c o m pli e d wit h all fi n a nci al a n d a d mi ni str ati v e r e q uir e m e nt s of t h e g o v er ni n g b o d y of t h e cli nic al i n stit uti o n a n d RI B O MI C a s t h e S p o n s or. I will o bt ai n writt e n i nf or m e d c o n s e nt fr o m e ac h st u d y s u bj ect pri or t o p erf or mi n g a n y st u d y -s p ecific pr oc e d ur e s.  
I u n d er st a n d t h at m y el ectr o nic si g n at ur e o n a n el ectr o nic c a s e r e p ort f or m i n dic at e s t h at t h e 
d at a t h er ei n h a s b e e n r e vi e w e d a n d acc e pt e d b y m e a s t h e I n v e sti g at or. I a gr e e t o m ai nt ai n t h e c o nfi d e nti alit y of all i nf or m ati o n r ec ei v e d or d e v el o p e d i n c o n n ecti o n wit h t hi s pr ot oc ol.  
 
 
 
I N V E S TI GA T O R:  Si g n at ur e/ D at e:     /    
 N a m e:    _ _ _ _ _ _ _  
( T y p e d or Pri nt e d) 
 A d dr e s s:    _ _ _ _ _ _ _  
 P h o n e:    _  
R B M -[ADDRESS_143593] a bl e S ol uti o n 
 Pr ot oc ol R B M -0 0 7 -0 0 3   
2  of 7 4    
A P P R O V E R S  
C o m p a n y/ S p o n s or si g n at or y   
   
  . 
 
 
 
    
  
  D o c u Si g n E n v el o p e I D: [ADDRESS_143594] a bl e S ol uti o n 
 Pr ot oc ol R B M -0 0 7 -0 0 3   
4 of  7 4     
2  S Y N O P SI S  
  
N a me of S p o ns or/ C o m p a n y:       
RI B O MI C U S A I nc.  [ADDRESS_143595]:  R B M - 0 0 7 i njecta ble s ol uti o n 
N a me of Acti ve I n gre die nt:  R B M -[ADDRESS_143596] u d y:  
A M ulti - Ce nter, O pe n La bel, T O F U E xte nsi o n St u d y A ssessi n g t he Efficac y a n d 
Safet y of A d diti o nal I ntra vitreal I njecti o ns of  R B M - 0 0 7 i n S u bjects wit h Wet A ge- relate d M ac ular  
D ege nerati o n  – R A M E N  St u d y  
St u d y Peri o d:  A p pr o xi matel y [ADDRESS_143597] e nr olle d: Oct o ber [ADDRESS_143598] c o m plete d: N o ve m ber 2 0 2 1 P h ase of De vel o p me nt:  P hase II  
Pri m ar y O bjecti ve:  To assess t he  safet y a n d efficac y of a d diti o nal i ntra vitreal i njecti o ns of R B M-0 0 7 ( 2. 0 m g/e ye ) 
i n s u bjects wit h wet a ge-relate d mac ular de ge nerati o n ( A M D) 
r olle d o ver fr o m T O F U St u d y 
( Pr ot oc ol R B M- 0 0 7- 0 0 2). 
Sec o n d ar y O bjecti ve:  To e val uate a nti -fi br otic effect f or R B M -[ADDRESS_143599] a bl e S ol uti o n 
 Pr ot oc ol R B M -0 0 7 -0 0 3   
5 of  7 4   Met h o d ol o g y: 
T his is a m ulti -ce nter, o pe n  la bel, e xte nsi o n st u d y a ssessi n g t he efficac y a n d safet y of a d diti o nal 
intra vitreal injecti o ns of R B M- [ADDRESS_143600] u d y. 
A p pr o xi matel y f ort y s u bjects wit h
 e x u dati ve a ge -relate d mac ular  de ge nerati o n ( A M D) 
will recei ve R B M- 0 0 7 i njecta ble sol uti o n ( 2. 0 m g/e ye)  
T he pri mar y e n d p oi nt of t he st u d y is at o ne m o nt h p ost t he last i njecti o n wit h safet y e val uati o n  t hr o u g h t w o m o nt hs
 p ost t he last i njecti o n . 
F or eli gi bilit y, s u bjects m ust be dia g n ose d wit h  e x u dati ve A M D i n t he st u d y e ye, f or w hic h 
pre vi o us T O F U mas ke d treat me nt ar ms wit h i ntra vitreal a nti -vasc ular e n d ot helial gr o wt h 
fact or (a nti-V E G F) a ge n t E ylea® a n d/ or R B M - [ADDRESS_143601] 6 visits t hat i ncl u de a 
Ba seli ne/ Da y 1 ( Visit 1), a n d m o nt hs 1- 5 ( Visit 2- 6) 
S u bjects are eli gi ble f or resc ue wit h E ylea® or ot her treat me nt at t he discreti o n of i n vesti gat or 
a n yti me d uri n g t he st u d y if o ne of t he f oll o wi n g resc ue criteria is met. 
 
Resc ue Criteri a:  
•  B C V A decrease of > 1 0 letters A N D  ce ntral s u bfiel d t hic k ness ( C S T) i ncrease of > 5 0 
µ m fr o m baseli ne ( visit 1 R A M E N).  
•  T he discreti o n of i n vesti gat or  
N u m ber of S u bjects ( pl a n ne d):  
A p pr o xi matel y [ADDRESS_143602] u d y:  
T he t otal st u d y peri o d f or eac h s u bject will i n cl u de a treat me nt peri o d a n d f oll o w u p peri o d 
(t otal u p t o fi ve m o nt hs ). 
R B M -[ADDRESS_143603] a bl e S ol uti o n 
 Pr ot oc ol R B M -0 0 7 -0 0 3   
6 of  7 4   M as ki n g:  
T his is a n o pe n la bel st u d y. T he  desi g nate d  Safet y  Re vie w  Tea m  ( S R T)  will  re vie w  t he  safet y  data  peri o dicall y  t o  
deter mi ne if t he safet y a n d t olera bilit y of t he d oses are acce pta ble.  
 
Di a g n osis a n d M ai n Criteri a f or I ncl usi o n:  
I ncl usi o n Criteri a: At Visit 1 ( B aseli ne ( D ay 1)) , s u bjects m ust meet all of t he f oll o wi n g i ncl usi o n criteria: 
1.  Pr o vi de si g ne d writte n i nf or me d c o nse nt o n t he I nstit uti o nal Re vie w B oar d  (I R B)/ Et hics 
C o m mittee ( E C) a p pr o ve d I nf or me d C o nse nt F or m (I C F) a n d pr o vi de a ut h orizati o n as 
a p pr o priate f or l ocal pri vac y re g ulati o ns. 
2.  Male or fe male [ADDRESS_143604] or (a nti -V E G F) a ge nts  E ylea
® a n d/ or R B M - 0 0 7 has 
n ot  de m o nstrate d i m pr o ve me nt i n visi o n; s u bjects wit h less t ha n [ADDRESS_143605] u d y e ye, as assesse d b y s pectral d o mai n o ptical 
c o here nce t o m o gra p h y ( S D - O C T).  
6.  A bse nce of ce ntral atr o p h y or reti nal e pit helial tear i n t he f o vea or a n y c o n diti o n pre ve nti n g V A i m pr o ve me nt
 i n t he st u d y e ye.  
7.  B C V A of 2 4 E T D R S letters ( 2 0/ 3 2 0) or better i n t he fell o w e ye . 
8.  Reas o na bl y clear me dia a n d s o me fi xati o n i n t he st u d y e ye t o all o w f or g o o d q ualit y  S D -
O C T a n d f u n d us  p h ot o gra p h y.  
R B M -[ADDRESS_143606] a bl e S ol uti o n 
 Pr ot oc ol R B M -0 0 7 -0 0 3   
7 of  7 4    
E xcl usi o n Criteri a:  
A s u bject wit h a n y of t he f oll o wi n g c o n diti o ns is n ot eli gi ble t o partici pate i n t he st u d y: Oc ul ar:  
1.  S u bjects w h ose visi o n ha ve i m pr o ve d > [ADDRESS_143607] u d y e ye: 
a. I ntra vitreal or peri oc ular c ortic oster oi d, wit hi n 9 0 da ys pri or t o Visit 1 ( Da y 1) 
a n d t hr o u g h o ut t he st u d y. 
b.  Fl u oci n ol o ne acet o ni de i ntra vitreal i m pla nt, wit hi n 1 2 m o nt hs pri or t o Visit 1 
( Da y 1) a n d t hr o u g h o ut t he st u d y. 
c. Vis u d y ne
® p h ot o d y na mic t hera p y, wit hi n 9 0 da ys pri or t o Visit 1 ( Da y 1) a n d  
t hr o u g h o ut t he st u d y. 
4.  U nc o ntr olle d or a d va nce d gla uc o ma, e vi de nce d b y a n i ntra oc ular press ure (I O P) of > 2 1 
m m H g or c u p/ disc rati o > 0. 8 w hile o n me dical t hera p y, or c hr o nic h y p ot o n y ( < 6 m m H g) 
i n t he st u d y e ye. 
5.  E vi de nce of a n y ot her oc ular disease ot her t ha n wet A M D i n t he st u d y e ye t hat ma y 
c o nf o u n d t he o utc o me of t he st u d y (e. g., acti ve dia betic reti n o pat h y, p osteri or u veitis,  pse u d o vitellif or m mac ular de ge nerati o n, m o derate/se vere m y o pi a). 
6.  Hist or y of vitrect o m y i n t he st u d y  e ye. 
7.  Nee d f or oc ular s ur ger y i n t he st u d y e ye d uri n g t he c o urse of t he st u d y. 
8.  Y A G laser ca ps ul ot o m y wit hi n 3 0 da ys pri or t o Visit 1 ( Da y 1) i n t he st u d y  e ye. 9.  I ntra oc ular s ur ger y, i ncl u di n g le ns re m o val or laser, wit hi n 9 0 da ys pri or t o Visit 1 
(Baseli ne ( Da y 1)) i n t he st u d y e ye. 
[ADDRESS_143608] u d y e ye. 
1 2.  Me dia  o pacit y  t hat  w o ul d  li mit  cli nical  vis ualizati o n,  f u n d us  p h ot ogra p h y,  f u n d us 
a ut ofl u orescence, or s pectral  d o mai n  o ptical  c o here nce  t o m o gra p h y  (S D -O C T ) 
e val uati o n i n t he st u d y e ye. 
[ADDRESS_143609] a bl e S ol uti o n 
 Pr ot oc ol R B M -0 0 7 -0 0 3   
8 of  7 4   N o n -Oc ul ar:  
[ADDRESS_143610] u d y: 
a. S yste mic treat me nt wit h a nti - V E G F a ge nts (e. g., be vaciz u ma b)  b.  A ge nts tar geti n g t he F G F- [ADDRESS_143611] u d y relate d 
pr oce d ures/ me dicati o ns.  
1 9.  Maj or s ur ger y wit hi n 9 0 da ys pri or t o Visit 1 ( Baseli ne ( Da y 1) ). Maj or s ur ger y is defi ne d 
as a n y s ur ger y i n v ol vi n g a ris k t o t he life of t he s u bject, i ncl u di n g a n y o perati o n u p o n a n 
or ga n wit hi n t he cra ni u m, c hest, a b d o me n, or pel vic ca vit y. 
2 0.  T hera pe u tic ra diati o n t o t he hea d or nec k wit hi n 9 0 da ys pri or t o Visit 1 ( Da y 1). 
[ADDRESS_143612] u g or de vice cli nical trials wit hi n 3 0 da ys pri or t o 
Visit 1 ( Baseli ne ( Da y 1) ) or pla n ni n g t o partici pate i n ot her i n vesti gati o nal dr u g or 
de vice cli nical trials f or t he d urati o n of t he st u d y. T his i ncl u des b ot h oc ular a n d n o n -oc ular cli nical  trials. 
[ADDRESS_143613] at hi g h ris k f or treat me nt c o m plicati o ns. 
2 3.  Fe males w h o are pre g na nt or lactati n g a n d fe males of c hil d-beari n g p ote ntial w h o are 
n ot  usi n g a de q uate  c o ntrace pti ve  preca uti o ns  (i.e., I U D, oral  c o ntrace pti ves, barrier  met h o d, or ot her c o ntrace pti o n dee me d a de q uate b y t he Cli nical I n vesti gat or). 
[ADDRESS_143614]:  
I ntra vitreal i njecti o n i n t he st u d y e ye. 
Criteri a f or E v al u ati o n:  
Effic ac y:  
T he pri mar y efficac y varia bl e assesse d at M o nt h 4: • Mea n c ha n ge i n B C V A fr o m Baseli ne   
 
T he sec o n dar y efficac y varia bles assesse d at M o nt h 4 : • Pr o p orti o n of s u bjects gai ni n g m ore t ha n 1 5 letters as meas ure d b y B C V A fr o m Baseli ne 
( 3-li ne gai ners)  
• Pr o p orti o n of s u bjects wit h B C V A : 1) gai n of ≥ 10 E T D R S letters; 2) gai n of ≥ 5 E T D R S 
letters; a n d 3)  l oss of ≥ 1 5 letter s fr o m B aseli ne 
• C ha n ge fr o m B aseli ne i n C S T a n d mac ular v ol u me b y S D- O C T  
• C ha n ge fr o m B aseli ne i n c haracteristics of s u breti nal h y per reflecti ve material (S H R M ) 
• C ha n ge fr o m B aseli ne i n c haracteristics of fi br osis  
• Pr o p orti o n of s u bjects t hat d o n ot re q uire a nti -V E G F resc ue treat me nt d uri n g f oll o w-u p 
peri o d 
• Mea n n u m ber of resc ue i njecti o ns   
• Pr o p orti o n of s u bjects re q uiri n g resc ue 
S afet y: 
T he safet y assess me nts will i ncl u de a d verse e ve nts ( A Es), pre g na nc y test, e xter nal oc ular 
e xa m, B C V A,  I O P ,  slit  la m p  bi o micr osc o p y,  i n direct  o p ht hal m osc o p y,  S D -O C T ,  f u n d us 
p h ot o gra p h y, f u n d us a ut ofl u oresce nce, vital si g ns a n d p h ysical e xa mi nati o n. 
 
St atistic al Met h o ds:  
T he pri mar y a nal ysis will be after t he st u d y is c o m plete d . All safet y a n d efficac y data will be 
s u m marize d wit h descri pti ve statistics. B C V A a n d C S T data will als o be prese nte d gra p hicall y. 
D ue t o t he e x pl orat or y nat ure of t his st u d y, t he sa m ple size was n ot base d o n a statistical p o wer.  
 
R B M -[ADDRESS_143615] C orrecte d Vis u al Ac uit y  ( B C V A) ............................................................................................. 3 9  
11. 2 Ce ntr al S u bfiel d T hic k ness ( C S T), M ac ul ar Vol u me ( M V), Fi br osis a n d S H R M  ....................... [ADDRESS_143616]  ................................................................................................................. 4 6  
1 2. 2. 9  F u n d us P h ot o gra p h y  .................................................................................................................. 4 6  
1 2. 2. 1 0  F u n d us A ut ofl u oresce nce  .......................................................................................................... 4 6  
1 2. 2. 1 1  S pectral D o mai n O ptical C o here nce To m o gra p h y ( S D -O C T)  .................................................. [ADDRESS_143617] u d y  P o p ul ati o ns  ............................................................................................................................. 4 8  
1 4. 4 H a n dli n g of Missi n g  Val ues  .............................................................................................................. 4 9  
1 4. 5 De m o gr a p hics a n d B aseli ne  C h ar acteristics  ................................................................................... 4 9  
1 4. 6 Effic ac y A n al yses  ............................................................................................................................... 4 9  
1 4. 6. 1  A nal ysis of Pri mar y Efficac y  E n d p oi nts  ................................................................................... 4 9  
1 4. 6. 2  A nal ysis of Sec o n dar y Efficac y  E n d p oi nts  ............................................................................... 4 9  
1 4. 7 S afet y A n al ysis  ................................................................................................................................... 5 0  
1 5 DI R E C T A C C E S S T O S O U R C E  D A T A/ D O C U M E N T S  ....................................................................... [ADDRESS_143618] u d y Is  C o m plete d  ........................................................................................................... 6 0  
2 1. 2 A p pe n di x B - Ele me nts of I nf or me d  C o nse nt  ................................................................................. 6 1  
2 1. 2. 1  El e me nts of I nf or me d  C o nse nt  .................................................................................................. 6 1  
2 1. 2. 2  A d diti o nal Ele me nts of I nf or me d  C o nse nt  ................................................................................ 6 1  
2 1. 3 A p pe n di x C - Decl ar ati o n of  Helsi n ki  ............................................................................................. 6 3  
W M A Decl ar ati o n of Helsi n ki - Et hic al Pri nci ples f or Me dic al Rese arc h I n v ol vi n g H u m a n S u bjects  ... 6 3  
2 1. 4 A p pe n di x D - Pr oce d ures f or  E x a mi n ati o ns  ................................................................................... 6 9  
2 1. 4. 1  De m o gra p hics/ Eli gi bilit y, Me dical/ S ur gical Hist or y a n d C o nc o mita nt Me dicati o n  ................. [ADDRESS_143619] a bl e S ol uti o n 
 Pr ot oc ol R B M -0 0 7 -0 0 3   
1 3  of  7 4   LI S T O F T A B L E S  
TA B L E 1: EM E R G E N C Y CO N T A C T IN F O R M A TI O N  .................................................................................. 3  
TA B L E 2: SC H E D U L E O F EV E N T S  ....................................................................................................... 2 2  
TA B L E 3: R B M -0 0 7  DO SI N G  .............................................................................................................. 3 5  
 
LI S T O F FI G U R E S  
 
FI G U R E 1: DE CI SI O N I O P  PR O C E S S F O R I V T IN J E C TI O N  ................................................................... 2 5  
FI G U R E 2: 0. [ADDRESS_143620] u d y pr ot oc ol. 
 
A b brevi ati o ns a n d Ter ms  
A b bre vi ati o n  E x pressi o n ( N a me) i n f ull  
A E(s)  a d verse e ve nt(s)  
A M D  a ge-relate d mac ular de ge nerati o n B C V A  best c orrecte d vis ual ac uit y  C N V  c h or oi dal ne o -vasc ularizati o n  
C R F  Case re p ort f or m  
C S T  ce ntral s u bfiel d t hic k ness
 
e C R F(s)  Electr o nic Case Re p ort F or m(s)  
E D C  E C  Electr o nic Data Ca pt ure  Et hics C o m mittee  
E SI(s)  e ve nt(s) of s pecial i nterest  
E T D R S  Earl y Treat me nt of Dia betic Reti n o pat h y St u d y  
F D A  F o o d a n d Dr u g A d mi nistrati o n  
F G F  fi br o blast gr o wt h fact or 
G C P  G o o d Cli nical Practice  
G L P  G o o d La b orat or y Practice  
I C F i nf or me d c o nse nt f or m 
I C H I nter nati o nal C o nfere nce o n Har m o nizati o n 
I E C I n de pe n de nt Et hics C o m mittee 
I N D I n vesti gati o nal Ne w Dr u g A p plicati o n 
I O P i ntra oc ular press ure 
I R B I nstit uti o nal Re vie w B oar d  
I T T i nte nt-t o-treat 
I V T i ntra vitreal  
L O C F  Last O bser vati o n Carrie d F or war d  
Me d D R A  Me dical Dicti o nar y f or Re g ulat or y Acti vities  
m g  N O A E L  milli gra m  n o o bser ve d a d verse effect le vel
 
µ L  micr oliter  
m L milliliter  
m m H g  milli meter of merc ur y  
S A E(s)  seri o us a d verse e ve nt(s) 
S A P  statistical a nal ysis pla n 
S D -O C T  
S H R M  s pectral d o mai n o ptical c o here nce t o m o gra p h y s u breti nal h y per reflecti ve material 
S R T
 Safet y Re vie w Tea m  
V E G F  vasc ular e n d ot helial gr o wt h fact or  
R B M -[ADDRESS_143621] a bl e S ol uti o n 
 Pr ot oc ol R B M -0 0 7 -0 0 3   
1 5  of  7 4   5  I N T R O D U C TI O N 
A ge -relate d  mac ular  de ge nerati o n  ( A M D)  is  t he  lea di n g  ca use  of  irre versi ble  visi o n  l oss  i n  
de vel o pe d c o u ntries. A M D is c haracterize d b y e xtracell ular matri x de p osits, k n o w n as dr use n, 
acc u m ulati n g bet wee n t he reti nal pi g me nt e pit heli u m a n d Br uc h’s me m bra ne. I n e x u dati ve or wet A M D , u n wa nte d bl o o d vessels gr o w i nt o t he  mac ula w hic h lea ds t o he m orr ha ge a n d s u breti nal 
fl ui d. I n a d diti o n, reti nal pi g me nt e pit helial detac h me nt, reti nal tears, fi br o vasc ular scarri n g a n d 
vitre o us  he m orr ha ge  ma y  occ ur.  T he  a berra nt  gr o wt h  of  lea k y  vessels  is  t he  res ult  of  l ocal  i nfla m mat or y res p o nses lea di n g t o disr u pti o n of t he bala nce of c yt o ki nes t hat c o ntr ol a n gi o ge nesis (Li m et al., 2 0 0 7 ). 
A n gi o ge nesis is a c o m ple x a n d c o or di nate d pr ocess of t he gr o wt h a n d s pr o uti n g of ne w bl o o d 
vessels fr o m pre -e xisti n g vasc ulat ure. Alt h o u g h se veral a n gi o ge nic fact ors ha ve bee n i de ntifie d, V E G F fa mil y pr otei ns, t heir rece pt ors a n d i ntracell ular si g nali n g m o lec ules a p pear t o be t he ke y me diat ors of a n gi o ge nesis ( Ka ne et al., 2 0 0 7). 
A p pr o xi matel y 1. 2 milli o n pers o ns i n t he U nite d States are esti mate d t o ha ve ne o vasc ular A M D 
a n d 9 7 0 0 0 0 t o ha ve ge o gra p hic atr o p h y; > [ADDRESS_143622] use n. T hese pre vale nce fi g ures are e x pecte d t o i ncrease b y a p pr o xi matel y 5 0 % ( C he w et al, 2 0 1 2 ; Frie d ma n et al, 2 0 0 4 ). Fr o m t he i nitial sta ge of dr y A M D, c haracterize d b y li p of usci n de p osits u n der t he reti na k n o w n as dr use n, 1 0 % are at ris k f or se vere, ac ute l oss of ce ntral visi o n d ue t o t he o nset of wet A M D, c haracterize d b y t he gr o wt h of a b n or mal c h or oi dal  ne o vasc ularizati o n ( C N V ) i n  t he  mac ula,  w hic h lea ds  t o  s u breti nal  blee di n g,  fl ui d e x u dati o n a n d fi br otic scar f or mati o n. O ver 2 0 0, 0 0 0 ne w patie nts eac h year i n t he U. S. de vel o p 
wet A M D ( Ferris et al ., 1 9 8 4). 
C urre nt F D A -a p pr o ve d t hera pi[INVESTIGATOR_014] f or A M D are pe ga pta ni b ( Mac u ge n
®), ra ni biz u ma b (L uce ntis®), 
afli berce pt ( E ylea®) a n d br ol uciz u ma b ( Be o v u®). Als o , off -la bel use of  ali q u ote d be vaciz u ma b 
( Avasti n®) is use d t o treat A M D. All of t hese m olec ules act a gai nst t he sa me tar get: vasc ular 
e n d ot helial  gr o wt h  fact or  ( V E G F).  V E G F,  a  p ote nt  e n d ot helial  cell  mit o ge n  a n d  vasc ular  
per mea bilit y fact or, is a maj or c o ntri b ut or t o t he pat h o ge nesis of ne o vasc ular A M D. Treat me nts wit h  a nti -V E G F  dr u gs,  w hic h  are  deli vere d  b y  fre q ue nt  i ntra vitreal  i njecti o ns,  ha ve  s h o w n  dra matic vis ual be nefits f or A M D patie nts ( Br o w n et al ., 2 0 0 6; Heier et  al., 2 0 1 2; Marti n et al ., 2 0 1 2 ). H o we ver, t here are s o me critical li mitati o ns; i n f or mal cli nical trials, des pi[INVESTIGATOR_040] c o nsiste nt m o nt hl y treat me nt, 2 3 % of e yes treate d m o nt hl y wit h ra ni biz u ma b pr ocee de d t o visi o n w orse t ha n 2 0/ 2 0 0, a n d 2 0 % t o 4 0 % fail t o res ol ve mac ular fl ui d e ve n after 2 years of t hera p y ( Br o w n et al ., 2 0 0 6 ; Heier et  al., 2 0 1 2). F urt her m ore, i n t he “real-w orl d” setti n g, patie nts recei ve i ntra vitreal i njecti o ns at m uc h l o wer fre q ue nc y t ha n t he esta blis he d pr ot oc ols, s o t hat o n a vera ge, l o n g-ter m 
vis ual o utc o mes i n A M D treat me nt are p o or ( R ofa g ha et al ., 2 0 1 3; Ma g uire et al ., 2 0 1 6). Fact ors 
ass ociate d wit h p o or visi o n o utc o mes, i n a d diti o n t o persiste nt e x u dati o n, i ncl u de mac ular atr o p h y a n d s u b mac ular fi br otic scar f or mati o n. T h us, t here is a n ee d f or a d diti ve or alter nati ve t hera p y t o a nti-V E G F treat me nts f or wet A M D.  
Fi br o blast gr o wt h fact or ( F G F) has bee n i m plicate d i n t he pat h o p h ysi ol o g y of b ot h a n gi o ge nesis 
a n d fi br osis i n reti nal diseases ( Sc h ultz a n d Gra nt, 1 9 9 1 ; Vi n di n g, 1 9 9 0 ). F G F c o m prises a fa mil y of 2 2 me m bers, i ncl u di n g F G F 2, ha vi n g ma n y bi ol o gical acti vities ( Bi kfal vi et al., 1 9 9 7 ). F G F [ADDRESS_143623] ure f or mati o n ( Str utz et al ., 2 0 0 2) a n d sti m ulates b ot h V E G F pr o d ucti o n a n d scar f o r mati o n i n reti na.  
R B M -[ADDRESS_143624] or (F G F 2 ) acti vit y (Ji n et al, 2 0 1 6), w hic h h ol ds anti-a n gi o ge nic a n d a nti-scarri n g d ual acti o n (Mats u da et al., 2 0 1 9 ) as well as a ne gati ve acti o n f or V E G F e x pressi o n (Bel g ore et al, 2 0 0 3 ). I n t he rat a n d m o use m o dels of laser-i n d uce d c h or oi dal ne o vasc ularizati o n, it s h o we d acti vit y after i ntra vitreal i njecti o n at d oses as l o w as 5 µ g/e ye (Mats u da et al., 2 0 1 9 ). I n t he laser-i n duce d c h or oi dal ne o vasc ularizati o n ( C N V) fi br osis m o del i n rats, it s h o we d acti vit y after i ntra vitreal i njecti o n at d oses as l o w as 1 5 µ g/e ye ( Mats u da et al., 2 0 1 9 ). It is h y p ot hesize d 
t o ha ve p ote ntial effects i n t he treat me nt of wet A M D beca use of t hese acti vities. T h us, t he S p o ns or 
pla ns t o e val uate t he safet y a n d bi oacti vit y of R B M -0 0 7 I njecta ble S ol uti o n as a n i ntra vitreal treat me nt f or e x u dati ve A M D. 
RI B O MI C  has  c o n d ucte d  a  P hase  I/II,  o pe n -la bel,  d ose-escalati n g,  se q ue ntial  c o h ort  st u d y  
assessi n g t he safet y, t olera bilit y a n d bi oacti vit y of a si n gle I V T i njecti o n of R B M-[ADDRESS_143625] or y wet A M D ( Pr ot oc ol R B M - 0 0 7- 0 0 1). T hree d ose le vels of R B M -0 0 7 ha ve bee n assesse d i n t his P hase I/II st u d y,  0. 2 m g/e ye, 1. 0 m g/e ye a n d 2. 0 m g/e ye. I n t his st u d y ( S U S HI), t here were n o re p orte d S A Es. N o d ose -de pe n de nt e ve nts were re p orte d a n d n o safet y c o ncer ns were i de ntifie d at all i n vesti gate d d oses. Oc ular A Es were re p orte d i n 3 s u bjects ( 3 3. 3 %). M ost c o m m o n A E was s u bc o nj u ncti val he m orr ha ge ( 2 s u bjects) a n d t his was c o nsi dere d t o be d ue t o t he i njecti o n pr oce d ure. T he o nl y dr u g relate d A E was mil d iritis t hat was res ol ve d after o ne day of t o pi[INVESTIGATOR_127349] d e ye dr o ps. 
T he P hase II T O F U  st u d y ( R B M- 0 0 7- 0 0 2) is c urre ntl y o n g oi n g, wit h t he first patie nt ra n d o mize d 
o n [ADDRESS_143626] patie nt visit (at wee k 2 4 ) i n J ul y 2 0 2 1. As of t he data c ut- off date of De vel o p me nt Safet y  U p date Re p ort ( D S U R) - R B M - 0 0 7 ( 1 9 J ul y 2 0 2 0), a t otal of 
[ADDRESS_143627] u dies, s u p p ort t he 
use of re peate d I V T i njecti o ns of 2. 0 m g /e ye of R B M - 0 0 7 i n h u ma ns i n t he P hase II T O F U 
e xte nsi o n cli nical trial, na mel y R A M E N  ( Pr ot oc ol R B M- 0 0 7- 0 0 3).
R B M -[ADDRESS_143628] a bl e S ol uti o n 
 Pr ot oc ol R B M -0 0 7 -0 0 3   
1 7  of  7 4   6  O B J E C TI V E S  
Pri m ar y O bjecti ve:  
To assess t he  safet y a n d efficac y of a d diti o nal i ntra vitreal i njecti o ns of R B M-0 0 7 ( 2. 0 m g/e ye ) 
i n s u bjects wit h wet a ge-relate d mac ular de ge nerati o n ( A M D) r olle d o ver fr o m T O F U St u d y. 
 
Sec o n d ar y O bjecti ve : 
To e val uate a nti -fi br otic effect f or R B M- [ADDRESS_143629] u d y.    
A p pr o xi matel y  f ort y s u bjects wit h  e x u dati ve a ge -relate d mac ular  de ge nerati o n ( A M D) 
will recei ve R B M- 0 0 7 I njecta ble S ol uti o n ( 2. 0 m g/e ye) . 
T he  pri mar y  e n d p oi nt  of  t he  st u d y  is  at o n e  m o nt h  p ost  t he  last  i njecti o n  wit h  safet y  
e val uati o n  t hr o u g h a d diti o nal t w o m o nt hs  p ost t he last i njecti o n . 
F or el igi bilit y, s u bjects m ust be dia g n ose d wit h  e x u dati ve A M D i n t he st u d y e ye, f or w hic h 
pre vi o us T O F U mas ke d treat me nt  ar ms wit h i ntra vitreal a nti -vasc ular e n d ot helial gr o wt h fact or (a nti-V E G F) a ge nt  E ylea
® a n d/ or R B M - [ADDRESS_143630] 6 visits t hat i ncl u de a Baseli ne/ Da y 1 ( Visit 1), a n d m o nt hs 1- 5 ( Visit 2- 6). 
S u bjects are eli gi ble f or resc ue wit h E ylea
® or ot her treat me nt at t he discreti o n of i n vesti gat or  
a n yti me d uri n g t he st u d y if o ne of t he f oll o wi n g resc ue criteria is met.      
 
Resc ue Criteri a:   
Eli gi bilit y criteria f or Resc ue are as f oll o w:   
 
•  B C V A decrease of > 1 0 letters A N D  ce ntral s u bfiel d t hic k ness ( C S T) i ncrease of > 5 0 µ m 
fr o m R A M E N baseli ne visit . 
•  T he discreti o n of i n vesti gat or. 
Resc ue t hera p y is defi ne d as I V T i njecti o n of E ylea® or ot her treat me nt at t he discreti o n of 
i n vesti gat or i n t he st u d y e ye.   
W he ne ver p ossi ble, RI B O MI C s h o ul d be n otifie d bef ore a n y resc ue pr oce d ure. If resc ue wit h a nti-V E G F a ge nt is c o nsi dere d, t he s u bject m ust recei ve t he i njecti o n of 
R B M - [ADDRESS_143631] be perf or me d after t he a d mi nistrati o n of 
eac h o ne o f t he i njecti o ns ( R B M- 0 0 7 a n d Resc ue treat me nt ):  
R B M -[ADDRESS_143632] a bl e S ol uti o n 
 Pr ot oc ol R B M -0 0 7 -0 0 3   
1 9  of  7 4   (all o p ht hal mic pr oce d ures t o be perf or me d i n t he treate d e ye) 
- Wit hi n 3 0 mi n utes f oll o wi n g eac h o ne of t he i njecti o ns: 
o  Slit -la m p bi o micr osc o p y 
o  I n direct o p ht hal m osc o p y 
 
- I O P will be meas ure d at 3 0 ( ± 1 0) mi n utes f oll o wi n g t he i ntra vitreal i njecti o n. 
- If p ost-i njecti o n I O P is > 2 1 m m H g after e ye massa ge a n d/ or a q ue o us ta p perf or me d per 
i n vesti gat or discreti o n, I O P meas ure me nt will be re peate d at 6 0 ( ± 1 0) mi n utes p ost-i njecti o n.   
- If p ost-i njecti o n I O P at 6 0 ( ± 1 0) mi n utes is > 2 1 m m H g after e ye massa ge a n d/ or a q ue o us ta p perf or me d per i n vesti ga t or discreti o n, I O P meas ure me nt will be re peate d at 9 0 ( ± 1 0) mi n utes p ost-i njecti o n.   
- If t here is a n i ncrease of ≥ 1 0 m m H g at 9 0 ( ± 1 0) mi n utes p ost-i njecti o n c o m pare d t o p re-i njecti o n I O P, t he s u bject s h o ul d be prescri be d a t o pi[INVESTIGATOR_2855] I O P-l o weri n g me dicati o n u ntil he or s he ret ur ns f or f oll o w- u p per t he Cli nical I n vesti gat or’s discreti o n (a n u nsc he d ule d visit ma y a p pl y).  
- O n t he ot her ha n d, a s u bject wit h I O P meas ure me nt of > 2 1 m m H g will be ma na ge d acc or di n g t o t he discreti o n of t he Cli nical I n vesti gat or.  
- T he  I O P i ncrease of ≥ 1 0 m m H g fr o m p re-i njecti o n A N D I O P meas ure me nt of > 2 1 m m H g will be re p orte d as a n  A E.  
• A q ue o us ta p ca n be perf or me d at a n y ti me per t he Cli nical I n vesti gat or`s discreti o n f or 
treat me nt or pre ve nti o n of i ncreasi n g i n t he I O P. 
  
7. 1. [ADDRESS_143633] u d y  (Pr ot oc ol N o. R B M - 0 0 7- 0 0 3), R B M-0 0 7 ( 2. 0 m g /e ye)  is bei n g teste d i n 
s u bjects wit h wet A M D. T he ma xi m u m a m o u nt of R B M-[ADDRESS_143634] u d y  (Pr ot oc ol N o. R B M - 0 0 7- 0 0 1), t hree d ose le vels of R B M- 0 0 7 
( 0. 2 m g, 1. 0 m g a n d 2. 0 m g) were teste d i n ni ne s u bjects wit h refract or y wet A M D. N o d ose-de pe n de nt e ve nts were re p orte d a n d n o safet y c o ncer ns were i de ntifie d at all i n vesti gate d d oses. M ost c o m m o n A E was s u bc o nj u ncti val he m orr ha ge ( 2 s u bjects, 2 2 %) . One case of mil d irritati o n was re p orte d. A ll oc ular A Es , e xce pt o ne , were c o nsi dere d t o be d ue t o t he i njecti o n pr oce d ure. O nl y  o ne  dr u g  relate d  A E  was  n ote d , w hic h  was  mil d  iritis  t hat  res o lve d  after  o ne  da y  a d mi nistrati o n of t o pi[INVESTIGATOR_127349] d dr o ps.    
A d diti o nall y, P hase II T O F U  st u d y ( Pr ot oc ol N o. R B M- 0 0 7-0 0 2) i n t he U nite d States is a 
ra n d o mize d, d o u ble mas ke d, acti ve c o ntr olle d st u d y assessi n g t he safet y a n d efficac y of re peate d 
i ntra vitreal i njecti o ns of R B M - 0 0 7 ( 2. 0 m g/e ye) m o n ot hera p y a n d i n c o m bi nati o n wit h E ylea
® 
c o m pare d t o E ylea® m o n ot hera p y i n s u bjects wit h e x u dati ve a ge -relate d mac ular de ge nerati o n 
R B M -[ADDRESS_143635] a bl e S ol uti o n 
 Pr ot oc ol R B M -0 0 7 -0 0 3   
2 0  of  7 4   ( w A M D). Ei g ht y- o ne ( 8 1 ) s u bjects wit h w A M D will be ra n d o ml y assi g ne d t o o ne of t hree 
treat me nt ar ms:  
Ar m 1: S ha m + R B M - 0 0 7 2. 0 m g/e ye   Ar m 2: R B M - 0 0 7 2. 0 m g/e ye  + E ylea
® 2. 0 m g/e ye   
Ar m 3: S ha m  + E ylea® 2. 0 m g /e ye 
S u bjects recei ve 4  m o nt hl y i ntra vitreal i njecti o ns of R B M - 0 0 7 ( 2. 0 m g) or R B M 0 - 0 0 7 ( 2. 0 m g) + 
s ha m i n t he first treat me nt ar m, 4 m o nt hl y i ntra vitreal i njecti o ns of R B M - 0 0 7 ( 2. 0 m g) or R B M -
0 0 7 ( 2. 0 m g) i n c o m bi nati o n wit h t w o E ylea® i njecti o ns at e ver y ot her m o nt h f or t he sec o n d ar m, 
a n d 4 m o nt hl y i ntra vitreal i njecti o ns of s ha m  or s ha m +  E ylea® e ver y ot her m o nt h i n t he t hir d 
treat me nt ar m.   
T he P hase II T O F U  st u d y ( R B M- 0 0 7- 0 0 2) is c urre ntl y o n g oi n g, wit h t he first patie nt ra n d o mize d 
o n [ADDRESS_143636] patie nt visit (at wee k 2 4) i n J ul y 2 0 2 1. As of t he data c ut- off date of De vel o p me nt Safet y  U p date Re p ort ( D S U R) - R B M - 0 0 7 ( 1 9 J ul y 2 0 2 0), a t otal of 
[ADDRESS_143637] u dies were c o n d ucte d wit h R B M -0 0 7 I njecta ble S ol uti o n b y 
b ot h s yste mic a n d oc ular r o utes. S yste mic t o xicit y was see n o nl y wit h hi g h d oses far a b o ve t h ose 
d oses c o nte m plate d f or oc ular a d mi nistrati o n. T he N O A E L i n G o o d La b orat or y Practice  (G L P ) 
i ntra vitreal m o n ke y st u dies is 1 m g/e ye. Usi n g a v ol u me of vitre o us of 2. 2 m L f or m o n ke y, t his is a c o nce ntrati o n of 0. 4 5 m g/ m L ( At su mi et al ., 2 0 1 3). T he h u ma n d oses f or t he first i n h u ma n st u d y ( R B M- 0 0 7- 0 0 1) were  0. 2 m g, 1. 0 m g a n d 2. 0 m g per e ye a d mi nistere d o nce. C o nsi deri n g t he val ue of h u ma n vitre o us t o be 5. 2 m L ( Pa n da -J o nas, 1 9 9 4), t hese c o nce ntrati o ns are 0. 0 3 8, 0. 1 9 a n d 0. 3 8 m g/ m L f or t hese cli nical d oses. T heref ore, t he N O A E L i n m o n ke y is [ADDRESS_143638] or w o ul d ha ve bee n e ve n hi g her if t he visc osit y a n d i njecta ble v ol u me f or R B M-0 0 7 I njecta ble S ol uti o n i n a ni mals ( m o n ke y a n d ra b bit) were n ot li miti n g para meters. A d diti o nall y, t he l o n g -ter m 
oc ular m o n ke y st u d y wit h m o nt hl y i njecti o n of R B M -0 0 7 at 1 m g/e ye m o n ot hera p y a n d R B M -
0 0 7 at 0. 5 or 1 m g/e ye  i n a d diti o n t o E ylea
® at 2 m g/e ye f or u p t o se ve n i njecti o ns di d n ot s h o w  
a n y treat me nt-relate d a d verse eff ect.  
Wit h re gar d t o s yste mic e x p os ure, t he hi g hest c o nce ntrati o n of R B M -0 0 7 see n i n plas ma after 
si n gle i ntra vitreal d osi n g was 2, 1 0 0 n g/ m L at a d ose of 1 m g/e ye i n m o n ke y a n d 6 5. 1  n g/ m L at a d ose of 0. 5 m g/e ye (i njecti o n t o b ot h e yes at a d ose of 0. 5 m g/e ye, t otal 1 m g/ b o d y) i n ra b bit. To xic o ki netic e val uati o n i n G L P s yste mic st u dies i n m o n ke y s u g gests t hat bl o o d le vel at w hic h t o xicit y  mi g ht  occ ur  is  6 9 1, 0 0 0  n g/ m L.  T h us,  e ve n  wit h o ut  c orrecti n g  f or  t he  b o d y  wei g ht  differe nces bet wee n a ni mals a n d h u ma ns, t he sa fet y mar gi n is 1 6 5 – 5, [ADDRESS_143639] a bl e S ol uti o n 
 Pr ot oc ol R B M -0 0 7 -0 0 3   
2 1  of  7 4   2. 0 m g/e ye f or h u ma n. If t he b o d y wei g ht f or a ni mals is ta ke n i nt o acc o u nt (ra b bit a n d m o n ke y at 
3 k g a n d h u ma n at 7 0 k g ), t he safet y mar gi n is 3, 8 5 0 – [ADDRESS_143640] u d y  
7. 3  Tre at me nt Assi g n me nt  
R B M -0 0 7 i njecta ble s ol uti o n 2. 0 m g ( 1 0 0 µ L of 2 0  m g/ m L)  will be a d mi nistere d b y I V T i njecti o n 
i n t he st u d y e ye.   
 
7. [ADDRESS_143641] meets all eli gi bilit y re q uire me nts at Scree ni n g Pr oce d ure - Visit 1 ( Baseli ne ( Da y 1)) , eac h su bject will c o nti n ue t o be assi g ne d wit h t he u ni q ue s u bject n u m ber  pr o vi de d i n T O F U st u d y. If a s u bject is disc o nti n ue d fr o m t he st u d y f or a n y reas o n, t he s u bject n u m ber will re mai n i n effect a n d will n ot be re use d. 
A Sc he d ule of E ve nts ca n be f o u n d bel o w a n d detaile d pr oce d ures f or e xa mi nati o ns ca n be f o u n d 
i n Secti o n 2 1. 4 , A p pe n di x D – Pr oce d ures f or E xa mi nati o ns.  
R B M -[ADDRESS_143642] u dy Visits  
 Visit 1  ( B aseli ne ( D ay 1)) 
Scree ni n g  Pr oce d ure : 
- Ascertai n t h e patie nt has s uccessf ull y e xite d T O F U st u d y. 
- Visit [ADDRESS_143643] u d y o ver its baseli ne. 
• E x plai n t he p ur p ose a n d details of t he st u d y t o t he s u bject a n d o btai n writte n i nf or me d c o nse nt pri or t o t he s u bject’s partici pati o n i n a n y st u d y relate d acti vit y. 
• Re vie w s u bject’s de m o gra p hic i nf or mati o n, me dical, s ur gical a n d me dicati o n  hist or y. 
• If t he s u bject c o nti n ues t o be eli gi ble f or t he st u d y, as k fe male s u bject w het her s he is p ost me n o pa usal ( Secti o n  2 1. 4. 4 ). Perf or m uri ne pre g na nc y test t o t he s u bject w h o a ns were d “ N o” t o t he q uesti o n. 
• Perf or m t he f oll o wi n g assess me nts (all o p ht hal mic pr oce d ures t o be perf or me d  o n b ot h e yes): 
- P h ysical e xa mi nati o n 
- Vital  si g ns 
- B C V A  ( E T D R S) 
- E xter nal oc ular e xa m  
- I O P  
- Slit -la m p bi o micr osc o p y 
- I n direct o p ht hal m osc o p y 
- S D -O C T  
- O C T  A n gi o gra p h y 
- F u n d us p h ot o gra p h y 
- F u n d us A ut ofl u oresce nce 
• Re vie w t he i ncl usi o n a n d e xcl usi o n criteria. D o n ot c o nti n ue scree ni n g a n y  s u bject w h o d oes n ot meet t he scree ni n g eli gi bilit y re q uire me nts. 
 
 
Tre at me nt Pr oce d ur e
R B M -[ADDRESS_143644] a bl e S ol uti o n 
 Pr ot oc ol R B M -0 0 7 -0 0 3   
2 4  of  7 4    
• After re vie w,  if t he s u bject c o nti n ues meeti n g all eli gi bilit y criteria, c o nfir m  t he st u d y e ye is 
sa me as i n T O F U st u d y, a n d pr ocee d f or  t he i njecti o n t hat will be a d mi nistere d as per dr u g la beli n g.   
• A d mi nister I V T R B M - [ADDRESS_143645] u g la beli n g. 
• T he f oll o wi n g assess me nts m ust be perf or me d after t he i njecti o n  ( o nl y o n t he treate d St u d y E ye):  
 
- Wit hi n [ADDRESS_143646]-i njecti o n: 
 Slit -la m p bi o micr osc o p y 
 I n direct o p ht hal m osc o p y 
- I O P will be meas ure d at 3 0 ( ± 1 0) mi n utes p ost- i njecti o n. 
- If p ost-i njecti o n I O P is > 2 1 m m H g after e ye massa ge  a n d/ or a q ue o us ta p perf or me d per i n vesti gat or discreti o n, I O P meas ure me nt will be re peate d at 6 0 ( ± 1 0) mi n utes p ost-i njecti o n.   
- If p ost-i njecti o n I O P at 6 0 ( ± 1 0) mi n utes is > 2 1 m m H g after e ye massa ge a n d/ or a q ue o us ta p perf or me d per i n vesti gat or discreti o n, I O P meas ure me nt will be re peate d at 9 0 ( ± 1 0) mi n utes p ost-i njecti o n.   
- If t here is a n i ncrease of ≥ 1 0 m m H g at 9 0 ( ± 1 0) mi n utes p ost-i njecti o n c o m pare d t o p re-i njecti o n I O P, t he s u bject s h o ul d be prescri be d a t o pi[INVESTIGATOR_2855] I O P-l o weri n g me dicati o n u ntil he or s he ret ur ns f or f oll o w- u p per t he Cli nical I n vesti gat or’s discreti o n (a n u nsc he d ule d visit ma y a p pl y).  
- O n t he ot her ha n d, a s u bject wit h I O P meas ure me nt of > 2 1 m m H g will be ma na ge d acc or di n g t o t he discreti o n of t he Cli nical I n vesti gat or. 
- T he  I O P i ncrease of ≥ 1 0 m m H g fr o m p re-i njecti o n A N D I O P meas ure me nt of > 2 1 m m H g will be re p orte d as a n  A E.  
 
• A q ue o us ta p ca n be perf or me d at a n y ti me per t he Cli nical I n vesti gat or`s discreti o n f or 
treat ment or pre ve nti o n of a n i ncrease i n t he I O P (see Fi g ure 1 ). 
 
• A E assess me nts m ust be perf or me d after I V T  i njecti o n. 
 • U pl oa d c ollecte d i ma ges ( S D -O C T  a n d F u n d us p h ot o gra p h y) of t he st u d y e ye t o t he E g n yte 
ser ver. 
• Sc he d ule t he s u bject t o ret ur n f or Visit 2 ( M o nt h 1  ( D 2 9 ± 4)). 
 
    
R B M -[ADDRESS_143647] a bl e S ol uti o n 
 Pr ot oc ol R B M -0 0 7 -0 0 3   
2 5  of  7 4   Fi g ur e Fi g ur e 1 1 : : D eci si o n I O P Pr oc e s s D eci si o n I O P Pr oc e s s   f or I V T I nj ecti o n f or I V T I nj ecti o n  
  
  
 
 
 Visit 2 ( M o nt h 1  ( D 2 9 ± 4)) 
• Pe rf or m t he f oll o wi n g assess me nts (all o p ht hal mic pr oce d ures t o be perf or me d o n b ot h 
e yes): 
- Q uer y f or A Es  
R B M -[ADDRESS_143648] or y a n d  me dicati o ns  
- B C V A  ( E T D R S) 
- E xter nal oc ular  e xa m 
- I O P  
- Slit -la m p bi o micr osc o p y 
- I n direct o p ht hal m osc o p y 
- S D -O C T  
- F u n d us p h ot o gra p h y 
 
• I njecti o n/ I O P c o ntr ol pr oce d ures are s a me as Visit 1 ( B aseli ne ( D a y 1)), descri be d i n 
Secti o n  7. 5. 1. 1   
• U pl oa d c ollecte d i ma ges ( S D -O C T  a n d F u n d us p h ot o gra p h y) of t he st u d y e ye t o t he E g n yte 
ser ver. 
• Sc he d ule t he s u bject t o ret ur n f or Visit 3 ( M o nt h 2 ( D 5 7 ± 4)). 
 
 
  
 
  
 
 
 
  
 
 
 
 
 
R B M -[ADDRESS_143649] a bl e S ol uti o n 
 Pr ot oc ol R B M -0 0 7 -0 0 3   
2 7  of  7 4    Visit 3 ( M o nt h 2  ( D 5 7 ± 4)) 
• Perf or m t he f oll o wi n g assess me nts (all o p ht hal mic pr oce d ures t o be perf or me d  o n b ot h e yes): 
- Q uer y f or A Es  
- U p date me dical hist or y a n d  me dicati o ns 
- B C V A  ( E T D R S) 
- E xte rnal oc ular e xa m  
- I O P  
- Slit -la m p bi o micr osc o p y 
- I n direct o p ht hal m osc o p y 
- S D -O C T  
- F u n d us p h ot o gra p h y 
 
• I njecti o n/ I O P c o ntr ol pr oce d ures are s a me as Visit 1 ( B aseli ne ( D a y 1)), descri be d i n 
Secti o n 7. 5. 1. 1   
• U pl oa d c ollecte d i ma ges ( S D -O C T  a n d F u n d us p h ot o gra p h y) of t he st u d y e ye t o t he E g n yte 
ser ver. 
• Sc he d ule t he s u bject t o ret ur n f or Visit 4 ( M o nt h 3  ( D 8 5 ± 4)).   
 
 Visit 4 ( M o nt h 3 ( D 8 5 ± 4)) 
• Perf or m t he f oll o wi n g assess me nts (all o p ht hal mic pr oce d ures t o be perf or me d  o n b ot h e yes): 
- Q uer y f or A Es  
- U p date me dical hist or y a n d  me dicati o ns  
- B C V A  ( E T D R S) 
- E xter nal oc ular e xa m  
- I O P 
- Slit -la m p bi o micr osc o p y 
- I n direct o p ht hal m osc o p y 
- S D -O C T  
- F u n d us p h ot o gra p h y  
• I njecti o n/ I O P c o ntr ol pr oce d ures are s a me as Visit 1 ( B aseli ne ( D a y 1)), descri be d i n 
Secti o n  7. 5. 1. 1   
• U pl oa d c ollecte d i ma ges ( S D - O C T a n d F u n d us p h ot o gra p h y) of t he st u d y e ye t o t he E g n yte 
ser ver. 
• Sc he d ule t he s u bject t o ret ur n f or Visit 5 ( M o nt h 4 ( D 1 1 3 ± 7 )). 
R B M -[ADDRESS_143650] a bl e S ol uti o n 
 Pr ot oc ol R B M -0 0 7 -0 0 3   
2 8  of  7 4    
 Visit 5 ( M o nt h 4  ( D 11 3 ± 7)): Pri m ary E n d p oi nt 
• Perf or m t he f oll o wi n g assess me nts (all o p ht hal mic pr oce d ures t o be perf or me d  o n b ot h 
e yes): 
- Q uer y f or A Es  
- U p date me dical hist or y a n d  me dicati o ns  
- B C V A  ( E T D R S) 
- E xter nal oc ular e xa m  
- I O P  
- Slit -la m p bi o micr osc o p y 
- I n direct o p ht hal m osc o p y 
- S D -O C T  
- O C T  A n gi o gra p h y 
- F u n d us p h ot o gra p h y 
- F u n d us a ut ofl u oresce nce    
• U pl oa d c ollecte d i ma ges ( S D - O C T, F u n d us p h ot o gra p h y a n d F u n d us a ut ofl u oresce nce ) of 
t he st u d y e ye t o t he E g n yte ser ver. 
• Sc he d ule t he s u bject t o ret ur n f or Visit 6 ( M o nt h 5  ( D1 4 1 ± 7 )).  
 
 Visit 6 / E xit ( M o nt h 5 ( D 1 4 1 ± 7)) 
• Perf or m t he f oll o wi n g  assess me nts:  
- Q uer y f or A Es  
- P h ysical E xa m  
- Vital Si g ns  
- U p date me dical hist or y a n d  me dicati o ns 
- Perf or m uri ne pre g na nc y test t o t he s u bject w h o a ns were d “ N o” t o t he q uesti o n o n 
p ost me n o pa usal at Visit 1 ( B aseli ne ( D ay 1)).  
- B C V A  ( E T D R S) 
- E xter nal oc ular e xa m  
- I O P 
- Slit -la m p bi o micr osc o p y 
- I n direct o p ht hal m osc o p y 
- S D -O C T  
- F u n d us p h ot o gra p h y 
• U pl oa d c ollecte d i ma ges ( S D -O C T a n d F u n d us p h ot o gra p h y) of t he st u d y e ye t o t he E g n yte 
ser ver. 
 
R B M -[ADDRESS_143651] u d y s pecifie d 
pr oce d ures as necessar y a n d rec or d t he i nf or mati o n o n t he U nsc he d ule d Visit f or m(s). 
R B M -[ADDRESS_143652] I ncl usi o n  Criteri a  
 
At Visit 1 ( B aseli ne ( D ay 1)) , s u bjects m ust meet all of t he f oll o wi n g i ncl usi o n criteria: 
1.  Pr o vi de si g ne d writte n i nf or me d c o nse nt o n t he I nstit uti o nal Re vie w B oar d  (I R B)/ Et hics 
C o m mittee ( E C) a p pr o ve d I nf or me d C o nse nt F or m (I C F) a n d pr o vi de a ut h orizati o n as 
a p pr o priate f or l ocal pri vac y  re g ulati o ns. 
2.  Male or fe male [ADDRESS_143653] or (a nti -V E G F) a ge nts  E ylea
® a n d/ or R B M - 0 0 7 has 
n ot  de m o nstrate d i m pr o ve me nt i n visi o n; s u bjects wit h less t ha n [ADDRESS_143654] u d y e ye, as assesse d b y s pectral d o mai n o ptical 
c o here nce t o m o gra p h y ( S D - O C T).  
6.  A bse nce of ce ntral atr o p h y or reti nal e pit helial tear i n t he f o vea or a n y c o n diti o n pre ve nti n g V A i m pr o ve me nt
 i n t he st u d y e ye.  
7.  B C V A of 2 4 E T D R S letters ( 2 0/ 3 2 0) or better i n t he fell o w e ye  
8.  Reas o na bl y clear me dia a n d s o me fi xati o n i n t he st u d y e ye t o all o w f or g o o d q ualit y  S D -
O C T a n d f u n d us p h ot o gra p h y.  
8. [ADDRESS_143655] u d y: Oc ul ar:  
1.  S u bjects w h ose visi o n ha ve i m pr o ve d > [ADDRESS_143656] u d y e ye: 
R B M -[ADDRESS_143657] a bl e S ol uti o n 
 Pr ot oc ol R B M -0 0 7 -0 0 3   
3 1  of  7 4   a. I ntra vitreal or peri oc ular c ortic oster oi d, wit hi n 9 0 da ys pri or t o Visit 1 ( Da y 1) 
a n d t hr o u g h o ut t he st u d y. 
b.  Fl u oci n ol o ne acet o ni de i ntra vitreal i m pla nt, wit hi n 1 2 m o nt hs pri or t o Visit 1 
( Da y 1) a n d t hr o u g h o ut t he st u d y. 
c. Vis u d y ne® p h ot o d y na mic t hera p y, wit hi n 9 0 da ys pri or t o Visit 1 ( Da y 1) a n d  
t hr o u g h o ut t he st u d y. 
4.  U nc o ntr olle d or a d va nce d gla uc o ma, e vi de nce d b y a n I O P of > 2 1 m m H g or c u p/ disc 
rati o > 0. 8 w hile o n me dical t hera p y, or c hr o nic h y p ot o n y ( < 6 m m H g) i n t he st u d y e ye. 
5.  E vi de nce of a n y ot her oc ular disease ot her t ha n wet A M D i n t he st u d y e ye t hat ma y 
c o nf o un d t he o utc o me of t he st u d y (e. g., acti ve dia betic reti n o pat h y, p osteri or u veitis,  
pse u d o vitellif or m mac ular de ge nerati o n, m o derate/se vere m y o pia).  
6.  Hist or y of vitrect o m y i n t he st u d y  e ye. 
7.  Nee d f or oc ular s ur ger y i n t he st u d y e ye d uri n g t he c o urse of t he st u d y. 
8.  Y A G laser ca ps ul ot o m y wit hi n 3 0 da ys pri or t o Visit 1 ( Da y 1) i n t he st u d y  e ye. 9.  I ntra oc ular s ur ger y, i ncl u di n g le ns re m o val or laser, wit hi n 9 0 da ys pri or t o Visit 1 
(Baseli ne ( Da y 1)) i n t he st u d y e ye. 
[ADDRESS_143658] u d y e ye or a d ne xa. 
1 4.  Prese nce of k n o w n acti ve t o x o plas m osis, i nacti ve t o x o plas m osis or t o x o plas m osis scar 
i n eit her e ye. 
1 5.  Prese nce of a n y f or m of oc ular mali g na nc y i ncl u di n g c h or oi dal mela n o ma i n eit her  e ye. 
  
N o n -Oc ul ar:  
[ADDRESS_143659] u d y: 
a. S yste mic treat me nt wit h a nti - V E G F a ge nts (e. g., be vaciz u ma b)  b.  A ge nts tar geti n g t he F G F- [ADDRESS_143660] u d y relate d 
pr oce d ures/ me dicati o ns.  
1 9.  Maj or s ur ger y wit hi n 9 0 da ys pri or t o Visit 1 ( Baseli ne ( Da y 1) ). Maj or s ur ger y is defi ne d 
as a n y s ur ger y i n v ol vi n g a ris k t o t he life of t he s u bject, i ncl u di n g a n y o perati o n u p o n a n 
or ga n wit hi n t he cra ni u m, c hest, a b d o me n, or pel vic ca vit y. 
R B M -[ADDRESS_143661] a bl e S ol uti o n 
 Pr ot oc ol R B M -0 0 7 -0 0 3   
3 2  of  7 4   2 0.  T hera pe utic ra diati o n t o t he hea d or nec k wit hi n 9 0 da ys pri or t o Visit 1 ( Da y 1). 
[ADDRESS_143662] u g or de vice cli nical trials wit hi n 3 0 da ys pri or t o 
Visit 1 ( Baseli ne ( Da y 1) ) or pla n ni n g t o partici pate i n ot her i n vesti gati o nal dr u g or de vice 
cli nical trials f or t h e d urati o n of t he st u d y. T his i ncl u des b ot h oc ular a n d n o n -oc ular cli nical trials. 
[ADDRESS_143663] at hi g h ris k f or treat me nt c o m plicati o ns. 
2 3.  Fe males w h o are pre g na nt or lactati n g a n d fe males of c hil d -beari n g p ote ntial w h o are n ot 
usi n g a de q uate c o ntrace pti ve preca uti o ns (i.e., I U D, oral c o ntrace pti ves, barrier met h o d, or ot her c o ntrace pti o n  dee me d a de q uate b y t he Cli nical I n vesti gat or).  
[ADDRESS_143664]’s st u d y partici pati o n f or reas o ns 
relate d t o t he best i nterest of t he s u bject. S u bjects w h o ter mi nate fr o m t he st u d y ma y be re place d. S u bjects ma y be ter mi nate d fr o m  t he st u d y d ue t o a n y of t he f oll o wi n g reas o ns: 
 
• N o n -c o m plia nce 
• L ost t o  f oll o w- u p 
• Pr ot oc ol vi olati o n  
• Wit h dra wal b y  s u bject 
• A Es  
• Deat h  
• Ot her  
If a s u bject is disc o nti n ue d fr o m t he st u d y bef ore c o m pleti n g Visit 6/ E xit ( M o nt h 5) ( D 1 4 1 ± 7)), 
t he n t o t he e xte nt p ossi ble, all assess me nts, i ncl u di n g safet y, t hat are sc he d ule d t o be perf or me d at 
Visit 6/ E xit s h o ul d be perf or me d o n t he da y of disc o nti n uati o n. 
R B M -[ADDRESS_143665]’s welfare ma y be gi ve n at t he discreti o n of 
t he Cli nical I n vesti gat or d uri n g t he st u d y. W he ne ver p ossi ble, c o nc o mita nt me dicati o ns s h o ul d be 
a d mi nistere d i n d osa ges t hat re mai n c o nsta nt t hr o u g h o ut t he st u d y. T he ge neric na me, i n dicati o n, 
r o ute of a d mi nistrati o n, fre q ue nc y, d ose, start date a n d st o p date (if a p plica ble) will be rec or de d f or eac h me dicati o n. 
9. 2. 1  Pr o hi bite d Me dic ati o ns or Tre at me nts  
A n y s yste mic treat me nts w it h a nti-V E G F a ge nts (e. g., be vaciz u ma b) are pr o hi bite d d uri n g t he 
st u d y. 
T he decisi o n t o a d mi nister a pr o hi bite d c o nc o mita nt me dicati o n or treat me nt d uri n g t he st u d y 
s h o ul d be ma de wit h t he safet y of t he s u bject as t he pri mar y c o nsi derati o n. W he ne ver p oss i ble, 
RI B O MI C s h o ul d be n otifie d bef ore a n y pr o hi bite d me dicati o n or treat me nt is a d mi nistere d or if 
t he per missi bilit y of a s pecific me dicati o n or treat me nt is i n q uesti o n. 
9. 2. 2  Resc ue  T her a p y  
Resc ue t hera p y is defi ne d as I V T i njecti o n of E ylea
® or a n y ot her treat me nt at t he discreti o n of 
i n vesti gat or i n t he st u d y e ye.   
W he ne ver p ossi ble, RI B O MI C s h o ul d be n otifie d bef ore a n y resc ue pr oce d ure. 
If resc ue wit h a nti-V E G F a ge nt is c o nsi dere d, t he s u bject m ust recei ve t he i njecti o n of 
R B M - 0 0 7 pri or t o  t he i njecti o n of a nti-V E G F a ge nt f or resc ue.  
Eli gi bilit y  criteria f or Resc ue are as f oll o w:  
•  B C V A decrease of > 1 0 letters A N D  ce ntral s u bfiel d t hic k ness ( C S T) i ncrease of > 5 0 µ m 
fr o m t he R A M E N  baseli ne  visit . 
•  T he discreti o n of i n vesti gat or.   
If resc ue is perf or me d, t he f oll o wi n g assess me nts m ust be perf or me d after t he a d mi nistrati o n of 
eac h o ne of t he i njecti o ns ( R B M-0 0 7 a n d Resc ue treat me nt ) (all o p ht hal mic pr oce d ures t o be perf or me d  i n t he treate d e ye): 
 
- Wit hi n 3 0 mi n utes f oll o wi n g eac h o ne of t he i njecti o ns:  
o  Slit -la m p bi o micr osc o p y o  I n direct o p ht hal m osc o p y 
R B M -[ADDRESS_143666] a bl e S ol uti o n 
 Pr ot oc ol R B M -0 0 7 -0 0 3   
3 4  of  7 4   - IO P will be meas ure d at 3 0 ( ± 1 0) mi n utes f oll o wi n g t he i ntra vitreal i njecti o n.  
- If p ost-i njecti o n I O P is > 2 1 m m H g after e ye massa ge a n d/ or a q ue o us ta p perf or me d per 
i n vesti gat or  discreti o n, I O P meas ure me nt  will  be  re peate d  at  6 0  ( ± 1 0)  mi n utes  p ost-i njecti o n.   
- If p ost-i njecti o n I O P at 6 0 ( ± 1 0) mi n utes is > 2 1 m m H g after e ye massa ge a n d/ or a q ue o us 
ta p perf or me d per i n vesti gat or discreti o n, I O P meas ure me nt will be re peate d at 9 0 ( ± 1 0) 
mi n utes p ost-i njecti o n.   
- If t here is a n i ncrease of ≥ 1 0 m m H g at 9 0 ( ± 1 0) mi n utes p ost-i njecti o n c o m pare d t o pre-i njecti o n I O P , t he s u bject s h o ul d be prescri be d a t o pi[INVESTIGATOR_2855] I O P-l o weri n g me dicati o n u ntil he or s he ret ur ns f or f oll o w -u p per t he Cli nical I n vesti gat or’s discreti o n (a n u nsc he d ule d visit ma y a p pl y). 
- O n t he ot her ha n d, a s u bject wit h I O P meas ure me nt of > 2 1 m m H g will be ma na ge d acc or di n g t o t he discreti o n of t he Cli nical I n vesti gat or. 
- T he I O P i ncrease of ≥ 1 0 m m H g fr o m pre -i njecti o n A N D I O P meas ure me nt of > 2 1 m m H g will be re p orte d as a n A E.  
•  A q ue o us  ta p  ca n  be  perf or me d  at  a n y  ti me  per  t he  Cli nical  I n vesti gat or`s  discreti o n  f or  
treat me nt or pre ve nti o n of i ncreasi n g i n t he I O P . 
 
9. [ADDRESS_143667] n u m ber o n t he cart o n la bel. After use, ret ur n t he vial i n t he cart o n, seal a n d i nitial t he cart o n. 
1 0. 5  L o a di n g t he Syri n ge  
<I n vesti gati o nal dr u g: R B M- 0 0 7 > 
1.  A sterile, si n gle -use [ADDRESS_143668] o m mar ki n g s, i ncl u di n g 0. 1 m L ( 1 0 0
 
µ L ), will be pr o vi de d se paratel y f or I V T i njecti o n of R B M -0 0 7. I nstr ucti o ns f or filli n g t he 
s yri n ge are as f oll o ws: 
2.  Re m o ve t he sterile, si n gle - use 2 5 0 μ L s yri n ge fr o m t he pac ka gi n g. 
3.  Attac h a 1 9 -ga u ge x 1 ½ i nc h filter nee dle t o t he s yri n ge. R B M -0 0 7 is dis pe nse d i n a  0. 5 ml 
fill i n a 2 m L vial. See Fi g ure 2 . 
4.  Usi n g sterile tec h ni q ue, caref ull y dra w u p a p pr o xi matel y 2 0 0 μ L of R B M -0 0 7 i nt o t he 
s yri n ge (suffic ie ntl y lar ger v ol u me t ha n 1 0 0 µ L is nee de d t o all o w f or dea d s pace i n s yri n ge 
a n d nee dles pri or t o I V T i njecti o n).  
5.  Re m o ve t he [ADDRESS_143669] u n ger wit h t he 1 0 0 µ L blac k mar k o n t he 
s yri n ge, e x pelli n g t he e xcess fl ui d dra w n u p. 
C.  E ns ure t here are n o air b u b bles wit hi n  t he s yri n ge or t he nee dle h u b pri or t o i njecti o n, 
a n d pri or t o e x pelli n g t he e xcess fl ui d dra w n u p. 
Fi g ur e Fi g ur e 2 2 : :  0. 0. 5 5   m L fill i n a 2 m L vi al m L fill i n a 2 m L vi al   
  
<I n vesti gati o nal dr u g > 
R B M -[ADDRESS_143670] u d y e ye s h o ul d be pre pare d as f oll o ws: 
1.  Dilate  p u pil  ( 1  %  m y driac yl  a n d  2. 5  %  p he n yle p hri ne  or  e q ui vale nt  a p plie d  t o pi[INVESTIGATOR_1306] y) 
a p pr o xi matel y [ADDRESS_143671] hetic ( 0. 5 % pr o paracai ne h y dr oc hl ori de o p ht hal mic 
s ol uti o n or a n e q ui vale nt t o pi[INVESTIGATOR_2855] o p ht hal mic a nest hetic). 
3.  A d mi nister 5 % p o vi d o ne i o di ne. 
4.  Use a sterile c ott o n -ti p pe d a p plicat or t o re m o ve e xcess fl ui d fr o m t he l o wer c o nj u ncti val sac. 5.  Ta ke 2 sterile c ott o n ti p pe d a p plicat ors a n d t h or o u g hl y s oa k wit h 0. 5 % pr o paracai ne t o pi[INVESTIGATOR_2855] 
a nest hetic e ye dr o ps or a n e q ui vale nt t o pi[INVESTIGATOR_2855] o p ht hal mic a nest hetic. Place t he s oa ke d 
a p plicat ors, si de b y si de, ge ntl y b ut fir ml y o n t he c o nj u ncti val s urface at t he  area of t he e ntr y site descri be d bel o w i n Ste p 2 ( Secti o n 1 0. 7 ) a n d h ol d i n place f or a p pr o xi matel y [ADDRESS_143672] u g A d mi nistr ati o n  
<I n vesti gati o nal dr u g: R B M- 0 0 7 > 
1.  Pr i or t o starti n g t he i njecti o n pr oce d ure, R B M- [ADDRESS_143673] u d y e ye s h o ul d ha ve bee n pre pare d as descri be d i n 
Secti o n  1 0. 6 . 
2.  T he e ntr y site f or i njecti o n is 4. 0 m m p osteri or t o t he c or neal li m b us. A cali per ma y be use d 
t o i de ntif y t he nee dle e ntr y site. 
3.  I nsert t he nee dle per pe n dic ular t o t he e ye wall at t he l ocati o n s pecifie d i n Ste p 2 (Secti o n 
1 0. 7 ) t o i nject t he st u d y s ol uti o n i nt o t he vitre o us ca vit y. N ote: If a q ue o us ta p is c o nsi dere d necessar y, it s h o ul d be perf or me d prefera bl y pri or t o i njecti o n of t he R B M - [ADDRESS_143674] t he e ntire R B M - 0 0 7 d ose v ol u me ( 1 0 0 µ L) a n d sl o wl y wit h dra w t he 
nee dle. D o n ot p ull bac k o n t he pl u n ger at a n y ti me pri or t o wit h dra wi n g t he nee dle.  
5.  Briefl y a p pl y press ure f or a p pr o xi matel y 3 0 sec o n ds t o t he nee dle e ntr y site wit h sterile 
c ott o n ti p pe d a p plicat or ( ma y be s ki p pe d per Cli nical I n vesti gat or's discreti o n). 
6.  Re m o ve t he e yeli d s pec ul u m a n d ri nse t he e ye wit h sterile e y e was h s ol uti o n.  
7.  Patc h t he st u d y e ye at t he Cli nical I n vesti gat or's discreti o n.  8.  Prescri be t o pi[INVESTIGATOR_2855] a nti bi otic per PI [INVESTIGATOR_127350] o n.  
 
[ADDRESS_143675] u d y staff will verif y t hat t he te m perat ure was mai ntai ne d at -2 0° C d uri n g tra nsit. T he cli nical s u p plies s hi p me nt f or m s h o ul d be c o m plete d, si g ne d, a n d ret ur ne d as directe d. A c o p y m ust be mai ntai ne d at t he site f or t he Pri nci pal I n vesti gat or's rec or ds.  
R B M -[ADDRESS_143676] u gs. T his rec or d will be ma de a va ila ble t o RI B O MI C ( or desi g nee) f or acc o u nti n g  f or  all  cli nical  s u p plies.  A n y  si g nifica nt  discre pa nc y  a n d/ or  deficie nc y  m ust  be  rec or de d wit h a n e x pla nati o n. 
All s u p plies se nt t o t he Pri nci pal I n vesti gat or m ust be acc o u nte d f or a n d i n n o case will st u d y dr u gs 
be use d i n a n y u na ut h orize d sit uati o n. It is t he res p o nsi bilit y of t he Pri nci pal I n vesti gat or t o e ns ure t hat a n y use d a n d u n use d s u p plies are a vaila ble t o RI B O MI C ( or desi g nee) t hr o u g h o ut t he st u d y. 
 
 
[ADDRESS_143677] C orrecte d Vis u al Ac uity  ( B C V A) 
Mea n c ha n ge i n B C V A fr o m Baseli ne at M o nt h [ADDRESS_143678] u d y. 
Pr o p orti o n of s u bjects wit h B C V A: 1) gai n of ≥ 1 5 E T D R S letters ( 3 -line gai ners); 2) gai n of ≥ 1 0 
E T D R S letters; 3) gai n of ≥ 5 E T D R S letters a n d 4) ≥ 1 5 letter l oss fr o m Baseli ne at M o nt h 4 are 
ot her sec o n dar y e n d p oi nts. 
T he vis ual ac uit y will be rec or de d usi n g t he E T D R S c hart a n d t otal n u m ber of letters at 4 meter 
a n d 1 meter will be rec or de d. T he “ n o n st o p pi n g” r ule m ust be a p plie d d uri n g t he E T D R S B C V A 
e val uati o n, c o nsi deri n g e ver y letter t he s u bject ca n rea d. If a s u bject c o ul d n ot rea d E T D R S c hart, 
Fi n ger C o u nts, Ha n d M oti o n, Li g ht Perce pti o n, or N o Li g ht Perce pti o n will be rec or de d.  
1 1. 2  Ce ntr al S u bfiel d T hic k ness ( C S T),  M ac ul ar Vol u me ( M V) , Fi br osis a n d S H R M 
C S T,  M V ,  fi br osis a n d S H R M are sec o n dar y efficac y varia bles, a n d c ha n ge i n C S T, M V, fi br osis 
a n d S H R M fr o m B aseli ne at M o nt h [ADDRESS_143679] u g(s). A n A E, t heref ore, 
ca n be a n u ni nte n de d si g n (i ncl u di n g a n a b n or mal la b orat or y fi n di n g), s y m pt o m, or disease t hat 
has cli nical si g nifica nce a n d is te m p orall y ass ociate d wit h t he use of a me dici nal (i n vesti gati o nal) 
pr o d uct, w het her or n ot relate d t o t he me dici nal (i n vesti gati o nal) pr o d uct.  
I n cli nical st u dies, a n u n desira ble me dical c o n diti o n occ urri n g at a n y ti me, i ncl u di n g B aseli ne or 
pre-treat me nt peri o d, ma y be rec or de d as a n A E e ve n if n o st u d y dr u g has bee n a d mi nistere d. 
A n y si g nifica nt a d verse c ha n ge i n a s u bject’s c o n diti o n fr o m B aseli ne, re gar dless of ca usalit y, is 
t o be c o nsi dere d a n A E, u nless t he c ha n ge is deter mi ne d t o be a c o nti n uati o n of a pre-e xisti n g 
c o n diti o n t hat is d oc u me nte d i n t he s u bject’s me dical hist or y.  H o we ver, a cli nicall y si g nifica nt 
w orse ni n g i n se verit y, i nte nsit y, or fre q ue nc y of a pre -e xisti n g c o n diti o n ma y i n dicate a n A E. I n 
a d diti o n, all c o n diti o ns t hat lea d t o h os pi[INVESTIGATOR_1314] o ns, defi ne d as a n o ver ni g ht h os pi[INVESTIGATOR_70213] y, are c o nsi dere d as A Es. T his i ncl u des pla n ne d electi ve s ur geries. 
Lac k of efficac y of t he st u d y dr u g(s) f or t he c o n diti o n bei n g i n vesti gate d is n ot c o nsi dere d a n A E 
u nless a cli nicall y si g nifica nt c ha n ge is assesse d b y t he Cli nical I n vesti gat or.    A n electi ve s ur gical pr oce d ure sc he d ul e d or pla n ne d pri or t o st u d y e ntr y is n ot c o nsi dere d a n A E if a n o ver ni g ht h os pi[INVESTIGATOR_70213] y is n ot re q uire d, a n d t he u n derl yi n g dia g n osis f or w hic h s ur ger y is t o be perf or me d s h o ul d be ca pt ure d i n t he me dical hist or y as a pre-e xisti n g c o n diti o n. T he s ur gical pr oce d ure s h o ul d als o i ncl u de t he ter m “electi ve” i n all re p orts. 
E n d o p ht hal mitis a n d reti nal detac h me nts ma y occ ur f oll o wi n g i ntra vitreal i njecti o ns. Patie nts 
s h o ul d be m o nit ore d f oll o wi n g t he i njecti o n. 
 
 Assess me nt of A dverse Eve nts  
Cli nical I n vesti gat or s will see k i nf or mati o n o n A Es at eac h s u bject c o ntact. S u bjects s h o ul d be as ke d, usi n g a ge neral, n o n -direct q uesti o n, if t here has bee n a n y c ha n ge i n t heir ge neral healt h. Direct q uesti o ni n g a n d e xa mi nati o n s h o ul d t he n be perf or me d as a p pr o priate. 
Se veri t y of t he A E s h o ul d be assesse d acc or di n g t o t he f oll o wi n g criteria: 
 
• Mil d: N o i nterfere nce wit h t he s u bject’s dail y acti vities; n o me dical i nter ve nti o n/t hera p y  
re q uire d 
• M o der ate: P ossi ble i nterfere nce wit h t he s u bject’s dail y acti vit ies; n o or mi ni mal me d ical 
i nter ve nti o n/t hera p y re q uire d 
• Se vere: C o nsi dera ble i nterfere nce wit h t he s u bj ect’s dail y acti vities; me dical 
i nter ve nti o n/t hera p y re q uire d 
Re gar dless of se verit y, s o me A Es ma y als o meet re g ulat or y seri o us criteria. Refer t o defi niti o ns 
a n d re p orti n g o f seri o us a d verse e ve nts ( S A Es) i n Secti o n [ADDRESS_143680] u g(s) t o eac h A E (relate d or n ot relate d). T he Cli nical I n vesti gat or s h o ul d deci de w het her, i n his or her me dical j u d g me nt, t here is a reas o na ble p ossi bilit y t hat t he R B M -0 0 7 i njecti o n c o ul d ha ve ca use d t he A E/ S A E base d o n f acts, e vi de nce, scie ntific rati o nales, a n d  cli nical  j u d g me nt.  W he n  assessi n g  ca usalit y,  t he  Cli nical  I n vest i gat or  ma y  c o nsi der  t he  f oll o wi n g  i nf or mati o n  w he n  deter mi ni n g  t he  relati o ns hi p  t o  t he  st u d y  dr u g(s)  f or  eac h  A E:  mec ha nis m  of  acti o n,  bi ol o gic  pla usi bilit y,  c o nf o u n di n g  ris k  fact ors  (i.e.,  me dical  hist or y,  
c o nc o mita nt me dicati o ns), te m p oral relati o ns hi p, dec halle n ge/rec halle n ge, a n d lac k of alter nati ve 
e x pla nati o n. It s h o ul d be s pecifie d if t he A E is relate d t o t he i njecti o n pr oce d ure a n d n ot t he st u d y dr u g. 
•  T he A E ma y be rec or de d as Rel ate d t o t he st u d y dr u g(s) if t here is a pla usi ble te m p oral 
relati o ns hip bet wee n t he o nset of t he A E a n d a d mi nistrati o n of t he st u d y dr u g(s ); a n d t he A E ca n n ot be rea dil y e x plai ne d b y t he s u bject’s cli nical state, c o nc urre nt ill ness, or c o nc o mita nt t hera pi[INVESTIGATOR_014]; a n d/ or t he A E f oll o ws a k n o w n patter n of res p o nse t o  t he st u d y dr u g(s); a n d/ or t he 
A E a bates or res ol ves u p o n disc o nti n uati o n of t he st u d y dr u g(s). 
•  Re p orti n g t he A E as N ot Rel ate d t o st u d y dr u g(s), ma y be c o nsi dere d if, f or e xa m ple, t here 
is g o o d e vi de nce t hat t he A E has a n eti ol o g y ot her t ha n t he st u d y dr u g(s) (e. g., pre-e xisti n g 
me dical  c o n diti o n,  u n derl yi n g  disease,  c o nc urre nt  ill ness,  or  c o nc o mita nt  me dicati o n);  a n d/ or t he A E has n o pla usi ble te m p oral relati o ns hi p t o a d mi nistrati o n of t he st u d y dr u g(s) (e. g., ca ncer dia g n ose d [ADDRESS_143681] u g(s)). 
 
 Re p or ti n g A dverse Eve nts  
A Es, w het her s p o nta ne o usl y re p orte d b y t he s u bject or n ote d b y a ut h orize d st u d y pers o n nel, will be rec or de d i n t he s u bject’s me dical rec or d a n d o n t he a p pr o priate A E e C R F . Eac h rec or de d A E will  be  descri be d  b y  its  d urati o n  (i.e.,  start  a n d  e n d  dates),  fre q ue nc y,  se verit y,  re g ulat or y  seri o us ness criteria if a p plica ble, s us pecte d relati o ns hi p t o t he st u d y dr u g(s), relati o n t o i njecti o n pr oce d ure, l ocati o n, acti o ns ta ke n a n d o utc o me. 
A Es t hat occ ur after a n y s u bject has pr o vi de d writte n i nf or me d c o nse nt, bef ore treat me nt, d uri n g 
treat me nt, or wit hi n [ADDRESS_143682] be rec or de d. To i m pr o ve t he q ualit y a n d precisi o n of ac q uire d A E data, Cli nical I n vesti gat ors s h o ul d o bser ve t he f oll o wi n g g ui deli nes: 
•  W he ne ver  p ossi ble,  use  rec o g nize d  me dical  ter ms  w he n  rec or di n g.  D o  n ot  use 
c oll o q uialis ms a n d/ or  a b bre viati o ns. 
•  If k n o w n, rec or d t he dia g n osis (i.e., disease or s y n dr o me) rat her t ha n c o m p o ne nt si g ns a n d 
s y m pt o ms a n d / or la b orat or y or test fi n di n gs (e. g., rec or d c o n gesti ve heart fail ure rat her t ha n 
d ys p nea, rales, a n d c ya n osis, a n d e nlar ge d heart o n c hest x -ra y). H o we ver, ot her e ve nts t hat 
are c o nsi dere d u nrelate d t o a n e nc o u ntere d s y n dr o me or disease s h o ul d be rec or de d as i n di vi d ual A Es (e. g., if c o n gesti ve heart fail ure a n d se vere hea dac he are o bser ve d at t he sa me ti me a n d are cli nicall y u nrelate d, eac h e ve nt s h o ul d be rec or de d as a n i n di vi d ual A E).  
•  If t he dia g n osis is n ot k n o w n, t he n rec or d t he lea di n g c o m p o ne nt si g n, s y m pt o m or test 
fi n di n g a n d descri be t he ot her cli nicall y relate d fi n di n gs i n t he narrati ve descri pti o n of t he case. A s us pecte d dia g n osis ca n be use d a n d descri be d as  s uc h. 
R B M -[ADDRESS_143683] a bl e S ol uti o n 
 Pr ot oc ol R B M -0 0 7 -0 0 3   
4 2  of  7 4   •  (e. g., rec or d s us pecte d or pr o ba ble m y ocar dial i nfarcti o n); t his has t o be u p date d i n t he 
cli nical data base o nce t he dia g n osis is c o nfir me d.  
•  A Es occ urri n g sec o n dar y t o ot her e ve nts (e. g., se q uelae) s h o ul d be i de ntifie d b y t he pri mar y 
ca use. A pri mar y A E, if clearl y i de ntifia ble, ge nerall y re prese nts t he m ost acc urate cli nical 
ter m. If a pri mar y A E is rec or de d, e ve nts occ urri n g sec o n dar y t o t he pri mar y e ve nt s h o ul d be descri be d i n t he narrati ve descri pti o n of t he case. F or e xa m ple: the s u bject de vel o pe d ort h ostatic  h y p ote nsi o n  a n d  s u bse q ue ntl y  fai nte d  a n d  fell  t o  t he  fl o or  w herei n  s he  
e xperie nce d a hea d tra u ma a n d nec k pai n. T he pri mar y A E i n t his e xa m ple is ort h ostatic 
h y p ote nsi o n. T he fall, hea d tra u ma a n d nec k pai n s h o ul d be descri be d i n t he narrati ve descri pti o n of t he case.  
•  F or i nter mitte nt e ve nts (e. g., i nter mitte nt hea dac he), t he e v e nt o nset date s h o ul d be rec or de d 
as t he date t he s u bject first starte d t o e x perie nce t he e ve nt a n d res ol uti o n date s h o ul d reflect w he n t he last occ urre nce res ol ve d or st o p pe d. Se parate A Es f or eac h e ve nt s h o ul d n ot be rec or de d. F or e xa m ple, if a s u bject e x perie nce d hea dac he o n 1 4 S E P 2 0 1 5 lasti n g f or t hree 
h o urs,  t he n  s u bse q ue ntl y  e x perie nce d  i nter mitte nt  e pis o des  of  hea dac he  e ver y  da y  f or  
a p pr o xi matel y 3 h o urs u ntil 2 1 S E P 2 0 1 5, t he n t he A E date of o nset is 1 4 S E P 2 0 1 5 a n d t he res ol uti o n date is 2 1 S E P 2 0 1 5. 
•  F or i nter mitte nt e ve nts, rec or d t he ma xi m u m se verit y of t he i n di vi d ual e ve nts. F or e xa m ple, 
if a s u bject c o m plai ns of i nter mitte nt hea dac hes f or o ne wee k a n d t he se verit y of eac h hea dac he ra n ges fr o m mil d t o m o derate, t he n t he se verit y w o ul d be m o derate. 
•  F or i nter mitte nt h os pi[INVESTIGATOR_1314] o ns occ urri n g f or a pri mar y A E (e. g., i n a s u bject wit h m ulti ple 
scler osis, c o m m o nl y k n o w n f or its rela psi n g a n d re mitti n g c o urse, i n s o me cases lea di n g t o m ulti ple h os pi[INVESTIGATOR_307] c o nfi ne me nts), t he s u bse q ue nt h os pi[INVESTIGATOR_1314] o ns s h o ul d be descri be d i n t he narrati ve descri pti o n of t he  case. 
•  If treat me nt was i nitiate d, i ncl u de t he treat me nt a n d d urati o n of t he me dicati o n(s) i n t he 
e C R F.  
 
[ADDRESS_143684], or 
preca uti o n. A n y a d verse e ve nt is c o nsi dere d a seri o us a d verse e ve nt if it res ults i n a n y of t he f oll o wi n g o utc o mes: 
•  Deat h  
•  Life  t hreate ni n g: 
A life -t hreate ni n g e ve nt is a n y e ve nt t hat places t he s u bject at i m me diate ris k of 
deat h fr o m t he  e ve nt as it occ urre d; it d oes n ot refer t o a n e ve nt t hat h y p ot heticall y mi g ht ha ve ca use d deat h if it were m ore se vere.  
•  H os pi[INVESTIGATOR_1314] o n, at t he mi ni m u m a n o ver ni g ht sta y 
•  A persiste nt or si g nifica nt  disa bilit y/i nca pacit y  
•  A c o n ge nital a n o mal y/ birt h defect  
R B M -[ADDRESS_143685] a bl e S ol uti o n 
 Pr ot oc ol R B M -0 0 7 -0 0 3   
4 3  of  7 4   •  Ot her me dicall y si g nifica nt  e ve nts: 
Ot her me dicall y si g nifica nt e ve nts are e ve nts t hat ma y n ot res ult i n deat h, be life - 
t hreate ni n g, or re q uire h os pi[INVESTIGATOR_1314] o n b ut ma y be c o nsi dere d a seri o us a d verse dr u g 
e x perie nce w he n, base d u p o n a p pr o priate me dical j u d g me nt, t he y ma y je o par dize 
t he s u bject a n d ma y re q uire me dical or s ur gical i nter ve nti o n t o pre ve nt o ne of t he 
o utc o mes liste d a b o ve. 
•  Si g ht t hreate ni n g e ve nt: 
A si g ht -t hreate ni n g e ve nt is a n y e ve nt t hat places t he s u bject at i m me diate ris k of per ma ne ntl y l osi n g visi o n i n eit her e ye as a direct res ult of t he e ve nt. It is defi ne d as a l oss of ≥ [ADDRESS_143686] be c o m plete d i n E D C wit h as m uc h i nf or mati o n a vaila ble wit hi n 2 4 h o urs of k n o wle d ge of t he e ve nt. 
To i m pr o ve t he q ualit y a n d precisi o n of ac q uire d S A E data, Cli nical I n vesti gat ors s h o ul d o bser ve 
t he f oll o wi n g g ui deli nes: 
•  De at h - Deat h is a n o utc o me of a n e ve nt. T he e ve nt t hat res ulte d i n t he deat h s h o ul d be 
rec or de d a n d re p orte d as a S A E.  
•  H os pit aliz ati o ns  f or  S ur gic al  or  Di a g n ostic  Pr oce d ures - T he  ill ness  lea di n g  t o  t he  
s ur gical or dia g n ostic pr oce d ure s h o ul d be rec or de d as t he S A E, n ot t he pr oce d ure itself. T he 
pr oce d ure s h o ul d be ca pt ure d i n t he case narrati ve as part of t he acti o n ta ke n i n res p o nse t o 
t he ill ness. 
W he n ne w si g nifica nt i nf or mati o n (i ncl u di n g t he o utc o me of t he e ve nt) is o btai ne d, t he Cli nical I n vesti gat or s h o ul d e nter t he i nf or mati o n directl y i nt o t he e C R F wit hi n [ADDRESS_143687]. 
 
 E x pe dite d Re p orti n g of Seri o us A dverse Eve nts  
RI B O MI C ( or desi g nee) will pr o vi de t he Pri nci pal I n vesti gat or wit h a re p orti n g c o ver letter a n d a n a n o n y mize d Me d Watc h [ADDRESS_143688] ( E SIs) are e ve nts t hat ma y re q uire s pecial atte nti o n f or t he p ur p oses of 
o n- g oi n g patie nt safet y re vie w d uri n g t his st u d y. T he f oll o wi n g are c o nsi dere d E SIs a n d s h o ul d be re p orte d o n t he a p pr o priate e C R F wit h as m uc h i nf or mati o n as a vaila ble wit hi n 2 4 h o urs of  k n o wle d ge of t he e ve nt: 
•  St u d y  me dic ati o n  a d mi nistr ati o n  err or – St u d y  me dicati o n  a d mi nistrati o n  err ors  
deter mi ne d t o be si g nifica nt b y t he Cli nical I n vesti gat or will be re p orte d a n d e val uate d as E SIs. E xa m ples of st u d y me dicati o n a d mi nistrati o n err ors ma y  i ncl u de, b ut are n ot li mite d 
t o: o ver d ose of st u d y me dicati o n a n d a d mi nistrati o n of st u d y me dicati o n fr o m a n i nc orrect 
k it. 
•  Pre g n a nc y  – T here  are  n o  c o ntr olle d  data  wit h  t he  i n vesti gati o nal  pr o d uct  i n  h u ma n  
pre g na nc y. It is re q uire d t hat w o me n of c hil d beari n g p ote ntial use effecti ve c o ntrace pti o n d uri n g t he st u d y a n d rec o m me n d f or [ADDRESS_143689] u d y e xit will be f oll o we d b y t he Cli nical I n vesti gat or ( or his/ her desi g nee) 
u ntil t he e ve nt is res ol ve d or deter mi ne d t o be irre versi ble, c hr o nic, or sta ble.  If t he s u bject is bei n g 
f oll o we d f or a S A E  be y o n d t he last pr ot oc ol sc he d u le d visit ( Mo nt h 5 ), t he visit s h o ul d be 
c o m plete d w he n sc he d ule d acc or di n g t o t he pr ot oc ol a nd t he A E  Date of Res ol uti o n a n d t he E n d of St u d y Date of C o m pleti o n s h o ul d be t he date w he n f oll o wi n g t he S A E e n de d. 
I n a d diti o n, o n a case- b y-case basis, RI B O MI C ( or des i g nee) ma y re q uest f oll o w u p be y o n d t he 
e n d of t he st u d y. 
If t he RI B O MI C P har mac o vi gila nce De part me nt re q uests f oll o w-u p o n a n i n di vi d ual S A E or 
desi g nate d  E SI,  t he  site’s  res p o nse  t o  f oll o w -u p  re q uests  s h o ul d  be  e maile d  t o  RI B O MI C  P har mac o vi gila nc e: t of u.safet y @ri b o mic.c o m.  
[ADDRESS_143690] u d y is utilizi n g a n electr o nic data ca pt ure ( E D C) s yste m f or data c ollecti o n. I n t he e ve nt 
t hat  t he  E D C  s yste m  is  u na vaila ble  f or  electr o nic  re p orti n g,  t he  ma n ual  bac k -u p  re p orti n g  pr oce d ures bel o w s h o ul d be f oll o we d: 
 
• C o m plete a n A E f or m  ma n uall y. 
• Attac h a c o ver s heet wit h y o ur c o ntact i nf or mati o n, i ncl u di n g site  n u m ber. 
• E mail t he A E f or m t o RI B O MI C P har mac o vi gila nce at t of u.safet y @ri b o mic.c o m 
W he n t he E D C s yste m bec o mes a vaila ble, u p date t he E D C s yste m wit h all pre vi o usl y re p orte d i nf or mati o n. 
 
R B M -[ADDRESS_143691] olic bl o o d press ures will be rec or de d i n milli meters of merc ur y ( m m H g) a n d heart rate will be rec or de d i n beats per mi n ute ( b p m).  
 
[ADDRESS_143692] C orrecte d Vis u al Ac uit y  
T he B C V A will be rec or de d usi n g t he E T D R S c hart a n d t otal n u m ber of letters at 4 meters a n d 1 
meter will be rec or de d. T he “ n o n st o p pi n g” r ule m ust be a p plie d d uri n g t he E T D R S B C V A e val uati o n, c o nsi deri n g e ver y letter t he s u bject ca n rea d. If a s u bject c o ul d n ot rea d E T D R S c hart, Fi n ger C o u nts, Ha n d M oti o n, Li g ht Perce pti o n, or N o Li g ht Perce pti o n will be rec or de d. 
 
[ADDRESS_143693] will be c o n d ucte d f or all fe males of c hil d beari n g p ote ntial.  
 
1 2. 2. 9  F u n d us P h ot o gr a p h y  Di gital c ol or f u n d us p h ot o gra p h y will be ta ke n f oll o wi n g t he pr oce d ure pr o vi de d b y t he s p o ns or. 
It will be perf or me d pri or t o a n y i ntra vitreal i njecti o ns. 
 
1 2. 2. 1 0 F u n d us A ut ofl u ores ce nce 
F u n d us  a ut o fl u orescence  will be ta ke n o n Visit 1 ( Baseli ne ( Da y 1))  a n d Visi t 5 ( M o nt h 4), 
f oll o wi n g t he pr oce d ure pr o vi de d b y t he s p o ns or. It will be perf or me d pri or t o a n y i ntra vitreal i njecti o ns. 
 
1 2. 2. 1 1 S pectr al D o m ai n O ptic al C o here nce To m o gr a p h y ( S D -O C T)  
S D -O C T  i ma ges  will  be  ta ke n  f oll o wi n g  t he  pr oce d ure  pr o vi de d  b y  t he  s p o ns or.   It  will  be  
perf or me d pri or t o a n y i ntra vitreal i njecti o ns.  
 
[ADDRESS_143694] u d y t hera p y, relati o n t o i njecti o n pr oce d ure, l ocati o n ( O D, O S, O U or n o n- oc ular ), acti o n ta ke n a n d o utc o me. Pri or t o e val uati n g t he i nci de nces, all A Es will be c o de d usi n g t he Me dical Dicti o nar y f or Re g ulat or y Acti vities (Me d D R A ). 
Oc ular  a n d  n o n -oc ular  A Es  will  be  s u m marize d  se paratel y.  See  Secti o n  [ADDRESS_143695] orat or y researc h, O C T A n gi o gra p h y will be ta ke n at selecte d sites  o n Vis it 1 
( Baseli ne ( Da y 1)) a n d Visit 5 ( M o nt h 4) i n all s u bjects.  
[ADDRESS_143696] u d y is c o m plete d. 
 
1 4. 1. 1  Pri m ar y  A n al ysis Descri pti ve s u m maries of t he f oll o wi n g efficac y a n d safet y meas ures will be pr o vi de d at t he M o nt h 
4 visit : 
• Mea n c ha n ge i n B C V A fr o m Baseli ne  
• Pr o p orti o n of s u bjects wit h B C V A: 1) gai n of ≥ 1 5 E T D R S letters ( 3 -li ne  gai ners);  2)  gai n       
of ≥ 1 0 E T D R S letters; 3) gai n of ≥ 5 E T D R S letters a n d 4) ≥ 1 5 letter l oss fr o m Baseli ne at 
M o nt h 4 are ot her sec o n dar y e n d p oi nts 
•  C ha n ge fr o m Baseli ne i n C S T, a n d mac ular v ol u me b y S D-O C T  
• C ha n ge fr o m Baseli ne i n c haracteristics of S H R M  • C ha n ge fr o m Baseli ne i n c haracteristics of fi br osis  • Pr o p orti o n of s u bjects t hat d o n ot re q uire a nti -V E G F treat me nt d uri n g f oll o w -u p peri o d 
(i ncl u di n g M o nt h 5) 
•  Mea n n u m bers of resc ue i njecti o ns i n t he m o n ot hera p y ar m 
•  Pr o p orti o n of s u bjects re q uiri n g resc ue (i ncl u di n g M o nt h 5) 
 
•  Safet y assess me nt i ncl u de A Es,  p h ysical e xa mi nati o n, vital si g ns, e xter nal oc ular e xa m, 
B C V A,  I O P, slit la m p bi o micr osc o p y, i n direct o p ht hal m osc o p y, S D -O C T, f u n d us 
p h ot o gra p h y,  f u n d us a ut ofl u oresce nce a n d pre g na nc y test   
•  A d diti o nal varia bles of i nterest will als o be pr o vi de d  
R B M -[ADDRESS_143697]  of  para meters  will  be  s u m marize d  
descri pti vel y. T he descri pti ve statistics will i ncl u de n u m ber of o bser vati o ns ( n), mea n, sta n dar d 
de viati o n, mi ni m u m, a n d ma xi m u m f or c o nti n u o us para meter a n d fre q ue nc y ( n) a n d perce nt ( %) f or cate g orical para meters. 
Details a b o ut t he statistical a nal yses f or t his st u d y will be pr o vi de d i n t he statistical a nal ysis pla n 
( S A P). 
All data ma ni p ulati o ns a n d descri pti ve s u m maries will be i m ple me nte d usi n g S A S
®, Versi o n 9. 1. [ADDRESS_143698] u d y p o p ulati o ns are defi ne d f or a nal ysis: I nte nti o n- t o-treat (I T T) a n d Safet y. 
•  I T T P o p ul ati o n: T he I T T p o p ulati o n will i ncl u de all s u bjects i n t he st u d y.  
•  S afet y P o p ul ati o n: T he Safe t y p o p ulati o n will i ncl u de all s u bjects w h o recei ve d at least o ne 
st u d y me dicati o n. It will be t he st u d y p o p ulati o n f or safet y a nal ysis. 
•  F ull A n al ysis Set: T he F ull A nal ysis Set ( F A S) will i ncl u de all s u bjects w h o recei ve d at 
least o ne st u d y me dicati o n a n d pr o vi de d at least o ne p ost - Baseli ne B C V A meas ure me nt. T he 
efficac y a nal ysis will be perf or me d o n t he F A S or a s u bset of t he F A S.  
R B M -[ADDRESS_143699] a bl e S ol uti o n 
 Pr ot oc ol R B M -0 0 7 -0 0 3   
4 9  of  7 4   •  Per -Pr ot oc ol  P o p ul ati o n: T he Per -Pr ot oc ol ( P P) P o p ulati o n is a s u bset of t he F A S. It 
i ncl u des all F A S s u bjects wit h o ut maj or pr ot oc ol vi olati o ns t hat c o ul d affect t he pri mar y 
efficac y e n d p oi nt. 
 
[ADDRESS_143700]- o bser vati o n- 
carrie d-f or war d ( L O C F) a p pr oac h. 
 
[ADDRESS_143701] u g  Gl o bal. 
 
1 4. 6  Effic acy A n alyses  
1 4. 6. 1  A n al ysis of Pri m ar y Effic ac y  E n d p oi nts  
• Mea n c ha n ge i n B C V A fr o m Baseli ne at M o nt h [ADDRESS_143702] u d y visit. 
T he pri mar y a nal ysis will be base d o n t he F A S a n d re peat a nal ysis will be perf or me d o n t he P P 
P o p ulati o n. 
 
1 4. 6. 2  A n al ys is of Sec o n d ar y Effic ac y E n d p oi nts  
T he f oll o wi n g will be a nal yze d at M o nt h 4: 
 •  Pr o p orti o n of s u bjects wit h B C V A: 1) gai n of ≥ 1 5 E T D R S letters ( 3 -li ne gai ners); 2) gai n of 
≥ 1 0 E T D R S letters; 3) gai n of ≥ 5 E T D R S letters a n d 4) ≥ 1 5 letter l oss fr o m Baseli ne  
•  C ha n ge fr o m Baseli ne i n C S T, a n d mac ular v ol u me b y S D- O C T  
•  C ha n ge fr o m Baseli ne i n c haracteristics of S H R M  
•  C ha n ge fr o m B aseli ne i n c haracteristics of fi br osis  
•  Pr o p orti o n of s u bjects t hat d o n ot re q uire a nti -V E G F treat me nt  d uri n g f oll o w - u p peri o d (i ncl u di n g M o nt h 5) 
•  Mea n n u m bers of resc ue i njecti o ns  
R B M -[ADDRESS_143703] a bl e S ol uti o n 
 Pr ot oc ol R B M -0 0 7 -0 0 3   
5 0  of  7 4   •  Pr o p orti o n of s u bjects re q uiri n g resc ue (i ncl u di n g M o nt h 5) 
 
1 4. 7  S afety A n alysis  
All safet y o utc o me meas ures will be s u m marize d descri pti vel y f or t he Safet y P o p ulati o n. T he 
safet y o utc o me meas ures i ncl u de a d verse e ve nts ( A Es), e xter nal oc ular e xa m, B C V A, slit -la m p bi o micr osc o p y, i n direct o p ht hal m osc o p y, i ntra oc ular press ure (I O P), vital si g ns,  pre g na nc y test, p h ysical e xa mi nati o n, f u n d us p h ot o gra p h y, f u n d us a ut ofl u oresce nce, a n d S D -O C T . 
A Es will be c o de d usi n g t he Me dical Dicti o nar y f or Re g ulat or y Acti vities ( Me d D R A).  S u bjects wit h a n y A Es will be ta b ulate d b y s yste m or ga n classificati o n a n d preferre d ter m s pecifie d 
i n t he Me d D R A. Si milarl y, s u bjects wit h a n y oc ular a n d n o n-oc ular A Es a n d E SIs will be ta b ulate d 
se paratel y. A Es, oc ular a n d n o n-oc ular, as well as E SIs will als o be s u m marize d b y relati o ns hi p t o 
treat me nt a n d ma xi m u m se verity. I n a d diti o n, S A Es a n d disc o nti n uati o ns d ue t o A Es will be s u m marize d. 
Oc ular safet y o utc o me meas ures will be s u m marize d usi n g descri pti ve statistics.  
 
 
1 5  DI R E C T A C C E S S T O S O U R C E  D A T A/ D O C U M E N T S  
T he  Pri nci pal  I n vesti gat or  will  all o w  re prese ntati ves  of  RI B O MI C’s  m o nit ori n g  tea m  ( or  
desi g nee),  t he  g o ver ni n g  i nstit uti o nal  re vie w  b oar d  (I R B),  t he  F D A,  a n d  ot her  a p plica ble  re g ulat or y a ge ncies t o i ns pect all st u d y rec or ds, e C R Fs, recr uit me nt materials a n d c orres p o n di n g p orti o ns  of  t he  s u bject’s  me dical  rec or ds  at  re g ular  i nter vals  t hr o u g h o ut  t he  st u d y.  T hese  i ns pecti o ns are f or t he p ur p ose of verif yi n g a d here nce t o t he pr ot oc ol, c o m plete ness, a n d e xact ness of t he data bei n g e ntere d o nt o t he e C R F, a n d c o m plia nce wit h t he  F D A or ot her re g ulat or y a ge nc y re gulati o ns. 
 
[ADDRESS_143704] u d y, RI B O MI C or a re prese ntati ve of 
RI B O MI C ( or desi g nee) will e val uate t he i n vesti gati o nal st u d y site t o:  
 • Deter mi ne t he a de q uac y of t he st u d y facilities. 
• Re vie w wit h t he Pri nci pal I n vesti gat or(s) a n d a ut h orize d st u d y staff t heir res p o nsi bilities 
wit h re gar d t o pr ot oc ol pr oce d ures a d here nce, a n d t he res p o nsi bilities of RI B O MI C ( or 
desi g nee). 
D uri n g t he st u d y, RI B O MI C ( or desi g nee) will ha ve re g ular c o ntact wit h t he i n vesti gati o nal site, 
f or t he f oll o wi n g: • Pr o vi de i nf or mati o n a n d s u p p ort t o t he Pri nci pal I n vesti gat or(s).  
• C o nfir m t hat facilities re mai n  acce pta ble. 
• Assess a d here nce t o t he pr ot oc ol a n d  G o o d Cli nical Practice (G C P ). 
• Perf or m i n vesti gati o nal pr o d uct acc o u nta b ilit y c hec ks a n d q ualit y c o ntr ol pr oce d ures. 
R B M -[ADDRESS_143705] a bl e S ol uti o n 
 Pr ot oc ol R B M -0 0 7 -0 0 3   
5 1  of  7 4   • E ns ure t he o n- g oi n g i m ple me ntati o n of acc urate data e ntr y i n t he  e C R F. 
• Perf or m s o urce data verificati o n, i ncl u di n g a c o m paris o n of t he data i n t he e C R Fs wit h t he 
s u bject’s me dical rec or ds a n d ot her rec or ds rele va nt t o t he st u d y. T his will re q uire direct 
access t o all ori gi nal rec or ds f or eac h s u bject (e. g., cli nic  c harts). 
• Rec or d a n d re p ort a n y pr ot oc ol de viati o ns n ot pre vi o usl y se nt t o RI B O MI C.  
• C o nfir m A Es a n d S A Es ha ve bee n pr o perl y d oc u me nte d o n e C R Fs a n d c o nfir m a n y S A Es 
ha ve bee n f or war de d t o RI B O MI C a n d t h ose S A Es t hat met criteria f or re p orti n g ha ve bee n f or war de d t o t he I R B or I E C. 
RI B O MI C  ( or  desi g nee)  ma y  re m otel y  access  t he  e C R Fs  at  a n y  ti me  d uri n g  t he  st u d y  f or  
ce ntralize d m o nit ori n g. RI B O MI C ( or desi g nee) will be a vaila ble bet wee n visits if a ut h orize d st u d y staff nee ds st u d y relate d i nf or mati o n or s u p p ort. 
 
1 5. 2  A u dits a n d  I ns pecti o ns 
T he Pri nci pal I n vesti gat or will all o w RI B O MI C ( or desi g n ee), t he g o ver ni n g I R B or I E C, a n d 
a p plica ble re g ulat or y a ge ncies t o a u dit a n d i ns pect a n y as pect of t he st u d y, i ncl u di n g all st u d y  rec or ds, e C R Fs, recr uit me nt materials, a n d c orres p o n di n g p orti o ns of t he s u bject’s c harts a n d me dical rec or ds at a n y ti me d u ri n g t he st u d y. T hese st u d y rec or ds m ust be retai ne d at t he st u d y site a n d ma de a vaila ble f or a u dits a n d i ns pecti o ns. T he p ur p ose of t hese a u dits a n d i ns pecti o ns is t o verif y a d here nce t o t he pr ot oc ol, c o m plete ness a n d acc urac y of t he e C R F data, a n d c o m plia nce 
wit h G o o d Cli nical Practice ( G C P) g ui deli nes a n d a p plica ble re g ulat or y re q uire me nts.  
T he Pri nci pal I n vesti gat or or a ut h orize d st u d y staff will n otif y RI B O MI C ( or desi g nee) s h o ul d t he 
site be a u dite d or i ns pecte d b y t he g o ver ni n g I R B or I E C, a n d a p plica ble re g ulat or y a ge ncies. 
RI B O MI C ( or desi g nee) will als o n otif y t he i n vesti gati o nal site of a n y k n o w n pe n di n g site a u dits 
or i ns pecti o ns pla n ne d b y RI B O MI C ( or desi g nee), g o ver ni n g I R B or I E C a n d re g ulat or y a ge ncies.  
 
[ADDRESS_143706] be mai ntai ne d b y t he Pri nci pal I n vesti gat or a n d ma de a vaila ble f or i ns pecti o n. 
 
1 6  Q U A LI T Y C O N T R O L A N D Q U A LI T Y  A S S U R A N C E  
1 6. 1  Q u ality C o ntr ol  
RI B O MI C ( or desi g nee) will pr o vi de i nstr ucti o nal material t o t he st u d y sites, as a p pr o priate; 
i ncl u di n g b ut n ot li mite d t o i nstr ucti o n o n t he pr ot oc ol, t he c o m pleti o n of e C R Fs, a n d st u d y 
pr oce d ures. RI B O MI C ( or desi g nee) will c o m m u nicate re g ularl y wit h site pers o n nel via mail, 
e mail, tele p h o ne, a n d/ or fa x; a n d ma ke peri o dic visits t o t he st u d y site. D uri n g t h ose visits, RI B O MI C ( or desi g nee) will perf or m s o urce data verificati o n wit h t he s u bject’s me dical rec or ds a n d ot her rec or ds rele va nt t o t he st u d y. U p o n recei vi n g t he e C R Fs, RI B O MI C ( or desi g nee) will 
R B M -[ADDRESS_143707] err ors i n data c ollecti o n. 
 
1 6. 2  Q u ality Ass ur a nce  
RI B O MI C ( or desi g nee) ma y c o n d uct a q ualit y ass ura nce a u dit at a n y ti me. 
R B M -[ADDRESS_143708] s u b mit writte n a p pr o val t o RI B O MI C ( or desi g nee) 
bef ore st u d y i nitiati o n. See Secti o n [ADDRESS_143709] u d y will als o be c o n d ucte d i n c o m plia nce wit h t he pr ot oc ol, G C P g ui deli nes, I nter nati o nal C o nfere nce o n Har m o nizati o n (I C H) g ui deli nes, t he Declarati o n of Helsi n ki. 
 
[ADDRESS_143710]’s le gall y a ut h orize d re prese ntati ve at t he ti me of c o nse nt. T he ori gi nal si g ne d a n d date d I C F will be retai ne d wit h t he st u d y rec or ds, a n d a c o p y of t he si g ne d  I C F will be gi ve n t o t he s u bject or t he s u bject’s le gall y a ut h orize d re prese ntati ve. 
R B M -[ADDRESS_143711] a bl e S ol uti o n 
 Pr ot oc ol R B M -0 0 7 -0 0 3   
5 4  of  7 4   1 8  D A T A H A N D LI N G A N D  R E C O R D K E E PI N G  
1 8. 1  I ns pecti o n of Rec or ds  
T he Pri nci pal I n vesti gat or will all o w RI B O MI C ( or desi g nee), t he g o ver ni n g I R B or I E C a n d 
a p plicable re g ulat or y a ge ncies t o i ns pect a n y as pect of t he st u d y, i ncl u di n g all st u d y rec or ds, 
e C R Fs, recr uit me nt materials a n d c orres p o n di n g p orti o ns of t he s u bject’s c harts a n d me dical 
rec or ds at a n y ti me d uri n g t he st u d y. T he p ur p ose of t hese i ns pecti o ns is to verif y a d here nce t o t he 
pr ot oc ol, c o m plete ness a n d acc urac y of t he e C R F data, a n d c o m plia nce wit h G C P g ui deli nes a n d a p plica ble re g ulat or y re q uire me nts.  
 
[ADDRESS_143712] u d y are t o be retai ne d b y t he Pri nci pal I n vesti gat or 
u ntil n otifie d b y RI B O MI C ( or desi g nee) t hat t he rec or ds ma y be destr o ye d. 
 
[ADDRESS_143713] u d y files, as well as t he res ults of dia g n ostic tests (e. g., la b orat or y tests). 
T he f oll o wi n g mi ni m u m i nf or mati o n s h o ul d be e ntere d i nt o t he s u bject’s me dical rec or d: 
 • T he date t he s u bject was e nr olle d a n d t he s u bject  n u m ber 
• T he st u d y pr ot oc ol n u m ber a n d t he na me of RI B O MI C U S A I nc. 
• T he date t hat i nf or me d c o nse nt was  o btai ne d 
• E vi de nce t hat t he s u bject meets st u d y eli gi bilit y re q uire me nts (e. g., me dical  hist or y, st u d y 
pr oce d ures a n d/ or e val uati o ns) 
• T he dates of all st u d y -relate d s u bject visits  
• E vi de nce t hat re q uire d pr oce d ures a n d/ or e val uati o ns were  c o m plete d 
• Use of a n y c o nc o mita nt me dicati o ns  
• D oc u me ntati o n of st u d y dr u g acc o u nta bilit y 
• Occ urre nce a n d stat us of a n y  A Es  
• T he date t he s u bject e xite d t he st u d y a n d a n otati o n as t o w het her t he s u bject c o m plete d or 
ter mi nate d earl y fr o m t he st u d y, i ncl u di n g t he reas o n f or earl y ter mi nati o n 
R B M -[ADDRESS_143714] mai ntai n detaile d rec or ds o n all s u bjects w h o pr o vi de i nf or me d 
c o nse nt. Data f or scree ne d a n d e nr olle d s u bjects will be e ntere d i nt o e C R Fs. Re vie w of t he e C R Fs will be c o m plete d re m otel y b y RI B O MI C ( or desi g nee). At desi g nate d i nter vals, a st u d y m o nit or will perf or m s o urce data verificati o n o n  site. D uri n g t h ose visits, RI B O MI C ( or desi g nee) will m o nit or  t he  s u bject  data  rec or de d  i n  t he  e C R F  a gai nst  s o urce  d oc u me nts  at  t he  st u d y  site.  RI B O MI C ( or desi g nee) will re vie w a n d e val uate e C R F data a n d use sta n dar d s yste m e dits, a n d ma y use ce ntralize d  m o nit ori n g e val uati o ns, t o detect err ors i n data c ollecti o n. At t he e n d of t he 
st u d y, a c o p y of t he c o m plete d e C R Fs will be se nt t o t he site t o be mai ntai ne d as st u d y rec or ds. 
R B M -[ADDRESS_143715] u d y are t he pr o pert y of RI B O MI C a n d s h o ul d n ot be discl ose d 
wit h o ut t he pri or writte n per missi o n of RI B O MI C. T hese data ma y be use d b y RI B O MI C n o w a n d i n  t he  f ut ure  f or  prese ntati o n  or  p u blicati o n  at  RI B O MI C’s  discreti o n  or  f or  s u b missi o n  t o  g o ver n me ntal re g ulat or y a ge ncies. RI B O MI C reser ves t he ri g ht of pri or re vie w of a n y p u blicati o n or prese ntati o n of data fr o m t his st u d y.  
I n si g ni n g t his pr ot oc ol, t he Pri nci pal I n vesti gat or a grees t o t he release of t he data fr o m t his st u d y 
a n d ac k n o wle d ges t he a b o ve p u blicati o n p olic y. 
R B M -[ADDRESS_143716] or  b y  h u ma n  a ortic  s m o ot h  m uscle  cells  b ut  n ot  b y  
e n d ot helial cells. E ur o pea n J o ur nal of Cli nical I n vesti gati o n 2 0 0 3; 3 3: [ADDRESS_143717] or - 2. 
E n d ocr Re v 1 9 9 7; 1 8( 1): [ADDRESS_143718] u d y Gr o u p: ra ni biz u ma b vers us 
verte p orfi n  f or  ne o vasc ular  a ge -relate d  mac ular  de ge nerati o n.  Ne w  E n gla n d  J o ur nal  of  Me dici ne 2 0 0 6; 3 5 5: [ADDRESS_143719] u d y  2  
( A R E D S 2):  St u d y  Desi g n  a n d  Baseli ne  C haracteristics  ( A R E D S 2  Re p ort  N u m ber  1).  O p ht hal m ol o g y 2 0 1 2; 1 1 9: 2 2 8 2- 8 9. 
5.  Ferris F L, III, Fi ne S L, H y ma n L. A ge -relate d mac ular de ge nerati o n a n d bli n d ness d ue t o 
ne o vasc ular mac ul o pat h y. Arc h. O p ht hal m ol 1 9 8 4; 1 0 2( 1 1): 1 6 4 0- 4 2. 
6.  Frie d ma n  D S,  O' C ol mai n  BJ,  M u n oz  B,  et  al.  Pre vale nce  of  a ge -relate d  mac ular  
de ge nerati o n i n t he U nite d States. Arc h O p ht hal m ol 2 0 0 4; 1 2 2( 4): 5 6 4- 7 2. 
7.  G or d o n , M., Kass, M. ( 2 0 0 1). Oc ular H y perte nsi o n Treat me nt St u d y ( O H T S), Ma n ual of 
Pr oce d ures, Versi o n 3. 0. Nati o nal Tec h nical I nf or mati o n Ser vice.  
8.  Heier J S, Br o w n D M, C h o n g V , et al. VI E W [ADDRESS_143720] u d y Gr o u ps: I ntra vitreal 
afli berce pt  ( V E G F tra p-e ye) i n wet a ge -relate d mac ular de ge nerati o n. O p ht hal m ol o g y 2 0 1 2; 1 1 9: [ADDRESS_143721] I nter nati o nal Wor ks h o p. A m J O p ht hal m ol 2 0 0 5; 2 8 0: 5 0 9- 1 6 
1 0.  Ji n L, N o na ka Y , Mi ya ka wa S, F uji wara M, Na ka m ura Y . D ual T hera pe utic Acti o n of a 
Ne utralizi n g A nti -F G F 2 A pta mer i n B o ne Disease a n d B o ne Ca ncer Pai n. M ol T her 2 0 1 6; 2 4: 1 9 7 4- 8 6. 
1 1.  Ka ne, F., Ca m p oc hiar o, P . C h or oi dal Ne o vasc ularizati o n. I n: Li m J, e dit or. A ge -Relate d 
Mac ular De ge nerati o n. 2
n d e diti o n, 2 0 0 7. p. 8 7- 9 5. 
1 2.  Li m JI a n d Ts o n g J W. Cli nical Feat ures of A ge -Relate d Mac ular De ge nerati o n. I n: Li m J, 
e dit or. Part II A ge -Relate d Mac ular De ge nerati o n. 2n d e diti o n, [ADDRESS_143722] or 2 A pta mer i n A ni mal M o dels of Reti nal Disease. M ol T her 2 0 1 9; 1 7: [ADDRESS_143723] or  treat me nt  of  ne o vasc ular  a ge -relate d  mac ular  de ge nerati o n: T he C o m paris o n of A ge -Relate d Mac ular De ge nerati o n Treat me nts Trials. 
O p ht hal m ol o g y 2 0 1 6; 1 2 3: [ADDRESS_143724] a bl e S ol uti o n 
 Pr ot oc ol R B M -0 0 7 -0 0 3   
5 8  of  7 4   1 5.  Marti n D F, Ma g uire M G, Fi ne S L et al. C o m paris o n of A ge -Relate d Mac ular De ge nerati o n 
Treat me nts Trials ( C A T T) Researc h Gr o u p. Ra ni biz u ma b a n d be vaciz u ma b f or treat me nt of 
ne o vasc ular  a ge -relate d  mac ular  de ge nerati o n:  2-year  res ults.  O p ht hal m ol o g y  2 0 1 2;  1 1 9 : 1 3 8 8- 8. 
1 6.  Me d Dra. Me d D R A M S S O, Me dical Dicti o nar y f or Re g ulat or y Acti vities, Versi o n 1 6. 1 2 0 1 3.  
1 7.  N usse n blatt R B, Palesti ne A G, C ha n C C, R o ber ge F. Sta n dar dizati o n of vitreal i nfla m mat or y 
acti vit y i n i nter me diate a n d p osteri or u veitis. O p ht hal m ol o g y 1 9 8 5; 9 2: 4 6 7 - 7 1. 
1 8.  Pa n da- J o nas S, J o nas J B, Ja k o bcz y k M, Sc h nei der U. Reti nal p h ot orece pt or c o u nt, reti nal 
s urface area, a n d o ptic disc size i n n or mal h u ma n e yes. O p ht hal m ol o g y 1 9 9 4; 1 0 1: [ADDRESS_143725] u d y ( S E V E N -U P). 
O p ht hal m ol o g y 2 0 1 3; 1 2 0: [ADDRESS_143726] ors. Eye  1 9 9 1; 1: [ADDRESS_143727] o nc e-dail y a n d t wice - dail y 
wit h ti m ol ol t wice -dail y i n patie nts wit h ele vate d i ntra oc ular press ure. S ur v O p ht hal m ol 
2 0 0 1; 4 5( [ADDRESS_143728] 2): S [ADDRESS_143729] or -2 i n e pit helial -
mese nc h y mal tra nsf or mati o n. Ki d ne y I nt 2 0 0 2; 6 1: 1 7 1 4 – 2 8. 
2 3.  S u n Wor ki n g, G. ( 2 0 0 5). P E R S P E C TI V E S Sta n dar dizati o n of  U veitis  N o me nclat ure  or 
Re p orti n g Cli nical Data. Res ults of t he First I nter nati o nal Wor ks h o p. A merica n J o ur nal of O p ht hal m ol o g y. 2 8 0( 3): 5 0 9- 1 6. 
2 4.  U S _ De pt _ Healt h _ A n d _ H u ma n _ Ser vices.  T he  Se ve nt h  Re p ort  of  t he  J oi nt  Nati o nal  
C o m mittee o n Pre ve nti o n, Detecti o n, E val uati o n, a n d Treat me nt of Hi g h Bl o o d  Press ure. T he Se ve nt h Re p ort of t he J oi nt Nati o nal C o m mittee o n Pre ve nti o n, Detecti o n, E val uati o n, a n d Treat me nt of Hi g h Bl o o d Press ure. Bet hes da  ( M D) [ADDRESS_143730] u d y of 1 0 0 0 a ge d i n di vi d uals. Acta O p ht hal m ol o gica 1 9 9 0; 6 8: 4 1 0 – [ADDRESS_143731] u g Dicti o nar y 
E n ha nce d ( W H O- D D E), Se pte m ber [ADDRESS_143732] a bl e S ol uti o n 
 Pr ot oc ol R B M -0 0 7 -0 0 3   
5 9  of  7 4   2 1  A P P E N DI C E S  
2 1. 1  A p pe n di x A - O bli g ati o ns of I nvesti g at ors 
I n s u m mar y, t he Cli nical I n vesti gat or has a gree d t o t he f oll o wi n g o bli gati o ns: 
•  O btai ni n g i nf or me d c o nse nt fr o m e ver y s u bject pri or t o t he s u bject’s partici pati o n i n a n y 
st u d y relate d acti vit y a n d mai ntai ni n g rec or ds of c o nse nt as part of t he st u d y rec or ds. 
•  O btai ni n g a p pr o val fr o m t he I R B bef ore i n v ol vi n g a n y s u bject i n a n y st u d y relate d acti vit y; 
s u b mitti n g verificati o n of t he a p pr o val t o t he S p o ns or; s u b mitti n g peri o dic pr o gress re p orts 
(at least a n n uall y) a n d fi nal re p ort t o I R B a n d t o t he S p o ns or. 
•  A p pr o vi n g t he pr ot oc ol a n d c o n d ucti n g t he st u d y acc or di n g t o t he pr ot oc ol a n d a p plica ble 
re g ulati o ns; i nf or mi n g t he S p o ns or of all de viati o ns fr o m t he pr ot oc ol. 
•  I nf or mi n g t he I R B of all pr ot oc ol a me n d me nts/ m o dificati o ns; se n di n g t he S p o ns or a c o p y 
of t he letter fr o m t he I R B a p pr o vi n g t h e a me n d me nt/ m o dificati o n. 
•  Re p orti n g t o t he S p o ns or a n d t he I R B a n y a d verse e x perie nces t hat occ ur i n t he c o urse of 
t he i n vesti gati o n, t his i ncl u des Seri o us A d verse E ve nts wit hi n 2 4 h o urs. 
•  Kee pi n g caref ul a n d acc urate rec or ds of all cli nical st u d y data (st u d y rec or ds m ust be 
c o nsi dera bl y m ore  e xact a n d c o m plete  t ha n t h ose  ke pt  i n or di nar y me dical practice); 
mai ntai ni n g rec or ds of all materials s u b mitte d t o t he I R B a n d of all acti o n b y t he I R B 
re gar di n g t he st u d y. 
•  Ma ki n g st u d y rec or ds a vaila ble f or i ns pecti o n  b y t he S p o ns or a n d re prese ntati ves of t he F o o d 
a n d Dr u g A d mi nistrati o n a n d ot her re g ulat or y a ge ncies; kee pi n g rec or ds u ntil n otifie d b y t he S p o ns or t hat t he y ma y be destr o ye d. 
•  Mai ntai ni n g pr o per c o ntr ol a n d d oc u me ntati o n of all test a n d c o ntr ol articles.  
•  S u b mitti n g t he f oll o wi n g rec or ds a n d re p orti n g t o t he S p o ns or. 
I. Pri or t o t he Be gi n ni n g of t he  St u dy  
•  A c urre nt c urric ul u m vitae ( C V) if n ot s u b mitte d t o RI B O MI C pre vi o usl y or if u p date d.  •  C Vs f or all s u b -I n vesti gat ors. 
•  A letter fr o m t he I R B i n dicati n g t hat t h e pr ot oc ol was a p pr o ve d, i ncl u di n g t he na me a n d 
a d dress of t he I R B.  
•  A c o p y of t he c o nse nt f or m a p pr o ve d b y I R B. •  A list of c urre nt me m bers of t he I R B.  
 
II. W hile t he St u dy Is i n  Pr o gress  
•  Ac k n o wle d g me nt of recei pt of t he test a n d c o ntr ol articles; d oc u me ntati o n of dis p ositi o n of 
all test a n d c o ntr ol  articles. 
R B M -[ADDRESS_143733] a bl e S ol uti o n 
 Pr ot oc ol R B M -0 0 7 -0 0 3   
6 0  of  7 4   •  Ori gi nal Case Re p ort F or ms f or eac h s u bject e nr olle d i n t he  st u d y. 
•  I nf or mati o n re gar di n g all de viati o ns fr o m t he pr ot oc ol. 
•  I nf or mati o n re gar di n g all a d verse me dical e ve nts occ urri n g t o a s u bject w hile e nr olle d i n t he 
st u d y. 
•  A n n ual pr o gress re p ort (if st u d y is o n g oi n g f or m ore t ha n o ne year). Letter fr o m t he I R B 
i n dicati n g a p pr o val of t he a n n ual pr o gress re p ort. 
III. O nce t he St u dy Is  C o m plete d  
•  Dis p ositi o n of all use d a n d/ or u n use d test a n d c o ntr ol articles, as well as d oc u me ntati o n of 
all dr u g acc o u nta bilit y. 
R B M -[ADDRESS_143734] ( or s u bject’s le gal re prese ntati ve) s h o ul d be pr o vi de d 
wit h a c o p y of t he si g ne d writte n I C F. 
1. State t hat t he st u d y i n v ol ves  R E S E A R C H.  
2. E x plai n t he P U R P O S E of t he researc h. 
3. Trial treat me nts a n d t he pr o ba bilit y f or ra n d o m assi g n me nt t o eac h  treat me nt. 
4. State t he e x pecte d D U R A TI O N of t he s u bject’s  partici pati o n.  
5. Descri be t he P R O C E D U R E S t o be  f oll o we d. 
6. I de ntif y a n y E X P E RI M E N T A L pr oce d ures. 
7. Descri be a n y reas o na bl y f oreseea ble RI S K S O R DI S C O M F O R T S t o t he  s u bject. 
8. Descri be a n y B E N E FI T S t o t he s u bject a n d res p o nsi bilit y f or t he s u bject or t o ot hers 
t hat ma y reas o na bl y be e x pecte d fr o m t he researc h. 
9. N ote a p pr o priate A L T E R N A TI V E pr oce d ures or c o urses of treat me nt, if a n y, t hat mi g ht 
be a d va nta ge o us t o t he s u bject. 
[ADDRESS_143735] will be mai ntai ne d.  
B.  N ote t hat t he F D A M A Y I N S P E C T t he rec or ds.  
1 1. F or researc h i n v ol vi n g m ore t ha n mi ni mal ris k, e x plai n if a n y C O M P E N S A TI O N or 
me dical treat me nts are a vaila ble s h o ul d i nj ur y occ ur. If s o, e x plai n (a) w hat t he y c o nsist of, O R ( b) w here f urt her i nf or mati o n ma y be  o btai ne d. 
[ADDRESS_143736] f or A N S W E R S t o perti ne nt q uesti o ns a b o ut (a) t he 
researc h, a n d ( b) researc h s u bjects’ ri g hts. 
B.  Tell w h o m t o c o ntact i n t he e ve nt of a researc h -relate d I NJ U R Y t o t he s u bject. 
1 3. State  t hat: 
A. Partici pati o n is  V O L U N T A R Y ,  
B. Ref usal t o partici pate will i n v ol ve N O P E N A L T Y or l oss of be nefits t o w hic h  
t he s u bject is ot her wise e ntitle d 
C. T he s u bject M A Y DI S C O N TI N U E partici pati o n at a n y ti me wit h o ut pe nalt y or 
l oss of be nefits t o w hic h t he s u bject is ot her wise e ntitle d. 
[ADDRESS_143737]:  
R B M -[ADDRESS_143738] ( or  t o t he 
e m br y o or fet us, if t he s u bject is or ma y bec o me pre g na nt) w hic h are c urre ntl y u nf oreseea ble.  
2.  A ntici pate d circ u msta nces u n der w hic h t he s u bject’s partici pati o n ma y be ter mi nate d b y t he 
I n vesti gat or wit h o ut re gar d t o t he s u bject’s c o nse nt. 
3.  A n y a d diti o nal c osts t o t he s u bject t hat ma y res ult fr o m partici pati o n i n t he  researc h. 
4.  T he c o nse q ue nces of a s u bject’s decisi o n t o wit h dra w fr o m t he  researc h a n d pr oce d ures f or 
or derl y ter mi nati o n of partici pati o n b y t he s u bject. 
5.  A state me nt t hat si g nifica nt ne w fi n di n gs de vel o pe d d uri n g t he c o urse of t he researc h, w hic h 
ma y relate t o t he s u bject’s willi n g ness t o c o nti n ue partici pati o n, will be pr o vi d e d t o t he 
s u bject. 
6.  T he a p pr o xi mate n u m ber of s u bjects i n v ol ve d i n t he st u d y. 
T he i nf or me d c o nse nt re q uire me nts i n t his pr ot oc ol are n ot i nte n de d t o pree m pt a n y  a p plica ble Fe deral, State, or l ocal la ws w hic h re q uire a d diti o nal i nf or mati o n t o be discl ose d f o r i nf or me d c o nse nt t o be le gall y effecti ve. 
N ot hi n g i n t his pr ot oc ol is i nte n de d t o li mit t he a ut h orit y of a p h ysicia n t o pr o vi de e mer ge nc y 
me dical care t o t he e xte nt t he p h ysicia n is per mitte d t o d o s o u n der a p plica ble Fe deral, State, or l ocal la w. 
 
R E F E R E N C E: [ADDRESS_143739] a bl e S ol uti o n 
 Pr ot oc ol R B M -0 0 7 -0 0 3   
6 3  of  7 4    
2 1. 3  A p pe n di x C - Decl ar ati o n of Helsi n ki  
W M A Decl ar ati o n of Helsi n ki - Et hic al Pri nci ples f or Me dic al Rese arc h I nv olvi n g 
H u m a n S u bjects  
 
Pre a m ble  
1. T he Worl d Me dical Ass ociati o n ( W M A) has de vel o pe d t he Declarati o n of Helsi n ki as a 
state me nt of et hical pri nci ples f or me dical researc h i n v ol vi n g h u ma n s u bjects, i ncl u di n g researc h 
o n i de ntifia ble h u ma n material a n d  data.  
T he Declarati o n is i nte n de d t o be rea d  as a w h ole a n d eac h of its c o nstit ue nt para gra p hs 
s h o ul d be a p plie d wit h c o nsi derati o n of all ot her rele va nt para gra p hs. 
2. C o nsiste nt wit h t he ma n date of t he W M A, t he Declarati o n is a d dresse d pri maril y t o 
p h ysicia ns. T he W M A e nc o ura ges ot hers w h o are i n v ol v e d i n me dical researc h i n v ol vi n g  h u ma n 
s u bjects t o a d o pt t hese pri nci ples.  
Ge ner al Pri nci ples  
3. T he Declarati o n of Ge ne va of t he W M A bi n ds t he p h ysicia n wit h t he w or ds, “ T he healt h 
of m y patie nt will be m y first c o nsi derati o n,” a n d t he I nter nati o nal C o de of Me dical Et hics 
declares t hat, “ A p h ysicia n s hall act i n t he patie nt's best i nterest w he n pr o vi di n g me dical  care.” 
4. It is t he d ut y of t he p h ysicia n t o pr o m ote a n d safe g uar d t he healt h, well- bei n g a n d ri g hts 
of patie nts, i ncl u di n g t h ose w h o are i n v ol ve d i n me dical researc h. T he p h ysicia n's k n o wle d ge a n d c o nscie nce are de dicate d t o t he f ulfil me nt of t his  d ut y. 
5. Me dical pr o gress is base d o n researc h t hat ulti matel y m ust i ncl u de st u dies  i n v ol vi n g 
h u ma n s u bjects. 
6. T he pri mar y p ur p ose of me dical researc h i n v ol vi n g h u ma n s u bjects is t o u n dersta n d t he 
ca uses, de vel o p me nt a n d effects of diseases a n d i m pr o ve pre ve nti ve, dia g n ostic a n d t hera pe utic 
i nter ve nti o ns ( met h o ds, pr oce d ures a n d treat me nts). E ve n t he best pr o ve n i nter ve nti o ns m ust be e val uate d c o nti n uall y t hr o u g h researc h f or t heir safet y, effecti ve ness, efficie nc y, accessi bilit y a n d  q ualit y. 
7. Me dical researc h is s u bject t o et hical sta n dar ds t hat pr o m ote a n d e ns ure res pect f or  all 
h u ma n s u bjects a n d pr otect t heir healt h a n d ri g hts. 
8. W hile t he pri ma r y p ur p ose of me dical researc h is t o ge nerate ne w k n o wle d ge, t his g oal 
ca n ne ver ta ke prece de nce o ver t he ri g hts a n d i nterests of i n di vi d ual researc h  s u bjects. 
9. It is t he d ut y of p h ysicia ns w h o are i n v ol ve d i n me dical researc h t o pr otect t he life, 
healt h, d i g nit y, i nte grit y, ri g ht t o self- deter mi nati o n, pri vac y, a n d c o nfi de ntialit y of pers o nal 
i nf or mati o n of researc h s u bjects. T he res p o nsi bilit y f or t he pr otecti o n of researc h s u bjects m ust 
al wa ys rest wit h t he p h ysicia n or ot her healt h care pr ofessi o nals a n d  ne ver wit h t he researc h s u bjects, e ve n t h o u g h t he y ha ve gi ve n c o nse nt. 
[ADDRESS_143740], i nce nti ves f or s u bjects a n d i nf or mati o n re gar di n g pr o visi o ns f or treati n g a n d/ or c o m pe nsati n g s u bjects w h o are har me d as a c o nse q ue nce of partici pati o n i n t he researc h st u d y. 
I n cli nical trials, t he pr ot oc ol m ust als o descri be a p pr o priate arra n ge me nts f or p ost-trial 
pr o visi o ns. 
Rese arc h Et hics C o m mittees  
[ADDRESS_143741] u d y’s fi n di n gs a n d c o ncl usi o ns. 
Pri v ac y a n d C o nfi de nti alit y   
[ADDRESS_143742]’s freel y- gi ve n 
i nf or me d c o nse nt, prefera bl y i n writi n g. If t he c o nse nt ca n n ot be e x presse d i n writi n g, t he n o n- writte n c o nse nt m ust be f or mall y d oc u me nte d a n d wit nesse d. 
All me dical researc h s u bjects s h o ul d be gi ve n t he o pti o n of bei n g i nf or me d a b o ut t he 
ge neral o utc o me a n d res ults of t he st u d y. 
[ADDRESS_143743]’s disse nt s h o ul d be  res pecte d. 
[ADDRESS_143744] u d y or t he patie nt’s decisi o n t o wit h dra w 
fr o m t he st u d y m ust ne ver a d versel y affect t he patie nt- p h ysicia n relati o ns hi p. 
[ADDRESS_143745] ora ge a n d/ or re use. T here ma y be e xce pti o nal sit uati o ns w here c o nse nt w o ul d be i m p ossi ble or i m practica ble t o o btai n f or s uc h researc h. I n s uc h sit uati o ns t he researc h ma y be d o ne o nl y after c o nsi derati o n a n d a p pr o val of a researc h et hics c o m mittee. 
Use of Pl ace b o  
[ADDRESS_143746] pr o ve n i nter ve nti o n(s), e xce pt i n t he f oll o wi n g circ u msta nces:  
W here n o pr o ve n i nter ve nti o n e xists, t he use of place b o, or n o i nter ve nti o n, is acc e pta ble; 
or 
W here f or c o m pelli n g a n d scie ntificall y s o u n d met h o d ol o gical reas o ns t he use of a n y 
i nter ve nti o n less effecti ve t ha n t he best pr o ve n o ne, t he use of place b o, or n o i nter ve nti o n is necessar y t o deter mi ne t he efficac y or safet y of a n i nter ve nti o n  a n d t he patie nts w h o recei ve a n y i nter ve nti o n less effecti ve t ha n t he best pr o ve n o ne, place b o, or n o i nter ve nti o n will n ot be 
s u bject t o a d diti o nal ris ks of seri o us or irre versi ble har m as a res ult of n ot recei vi n g t he best 
pr o ve n i nter ve nti o n. 
E xtre me c are m ust be ta ke n t o a v oi d a b use of t his o pti o n. 
P ost -Tri al Pr o visi o ns  
[ADDRESS_143747] a bl e S ol uti o n 
 Pr ot oc ol R B M -0 0 7 -0 0 3   
6 8  of  7 4   i nf or me d c o nse nt fr o m t he patie nt or a le gall y a ut h orize d re prese ntati ve, ma y use a n u n pr o ve n 
i nter ve nti o n if i n t he p h ysicia n's j u d g me nt it offers h o pe of sa vi n g life, re-esta blis hi n g healt h or alle viati n g s ufferi n g. T his i nter ve nti o n s h o ul d s u bse q ue ntl y be ma de t he o bject of researc h, desi g ne d t o e val uate its safet y a n d efficac y. I n all cases, ne w i nf or mati o n m ust be rec or de d a n d, w here a p pr o priate, ma de p u blicl y  a vaila ble.   
W M A Declarati o n of Helsi n ki - Et hical Pri nci ples f or Me dical Researc h I n v ol vi n g H u ma n S u bjects  
A d o pte d b y t he 1 8t h W M A Ge neral Asse m bl y, Helsi n ki, Fi nla n d, J u ne 1 9 6 4 a n d a me n de d b y t he:  [ADDRESS_143748] W M A Ge neral Asse m bl y, H o n g K o n g, Se pte m ber 1 9 8 9  
4 8t h' Wl' v.I A Ge neral Asse m bl y; S o merset West, Re p u blic of S o ut h Africa, Oct o ber [ADDRESS_143749] o ber 2 0 0 2 ( N ote of Clarificati o n a d de d) [ADDRESS_143750] o ber 2 0 0 4 ( N ote of Clarificati o n a d de d)  [ADDRESS_143751] a bl e S ol uti o n 
 Pr ot oc ol R B M -0 0 7 -0 0 3   
6 9  of  7 4    
2 1. 4  A p pe n di x D - Pr oce d ures f or  E x a mi n ati o ns 
2 1. 4. 1  De m o gr a p hics/ Eli gi bilit y, Me dic al/ S ur gic al Hist or y a n d C o nc o mit a nt Me dic ati o n 
De m o gra p hics/ Eli gi bilit y, me dical/s ur gical hist or y a n d c o nc o mita nt me dicati o n will be o btai ne d 
t hr o u g h s u bject i nter vie ws at Scree ni n g ( Da y - 2 8 t o Da y -1). Me dical hist or y a n d c o nc o mita nt me dicati o ns will be o btai ne d t hr o u g h s u bject i nter vie ws at eac h visit.  
 
2 1. 4. 2  P h ysic al  E x a mi n ati o n 
A f ull b o d y s yste matic p h ysical e xa mi nati o n will be c o n d ucte d d uri n g Visit 1 ( Baseli ne ( Da y 1)) . 
Cli nical I n vesti gat or o r a n e xter nal i nter nist will c o nfir m s u bject’s o verall c o n diti o n n oti n g a n y a b n or malities b y a re vie w of t he f oll o wi n g s yste ms: e. g., hea d, nec k, t h yr oi d, ears, n ose, t hr oat, m o ut h, t o n g ue, res pi[INVESTIGATOR_1305] y, car di o vasc ular, a b d o me n, a n d ne ur ol o gical. 
T he Cli nical I n vesti gat or will assess s u bject’s o verall c o n diti o n t o deter mi ne q ualificati o n f or st u d y 
e ntr y c o nsi deri n g p ossi ble class effects of R B M - 0 0 7.   
 
2 1. 4. 3  Vit al Si g ns  
Bl o o d press ure a n d heart rate will be meas ure d at Visit 0/ Scree ni n g ( Da y - 2 8 t o Da y - 1) usi n g an 
a ut o mate d  or  ma n ual  bl o o d  press ure  m o nit or.  S yst olic  a n d  diast olic  bl o o d  press ures  will  be  rec or de d i n milli meters of merc ur y ( m m H g) a n d heart rate will be rec or de d i n beats per mi n ute ( b p m). 
I n  acc or da nce  wit h  t he  rec o m me n dati o ns  of  t he  J oi nt  Nati o nal  Co m mittee  o n  Pre ve nti o n,  
Detecti o n,  E val uati o n,  a n d  Treat me nt  of  Hi g h  Bl o o d  Press ure  (U S _ De pt _ Healt h _a n d _ H u ma n _ Ser vices, 2 0 0 4 ), t he f oll o wi n g meas ure me nt pr oce d ure will be use d t o meas ure vital si g ns:  
•  S u bject s h o ul d n ot s m o ke or i n gest caffei ne wit hi n t he 3 0 -mi n ute peri o d i m me diatel y bef ore 
t he meas ure me nt.  
•  S u bject s h o ul d be seate d q uietl y i n a c hair wit h t he bac k s u p p orte d, feet o n t he  fl o or, ar m 
bare d, a n d ar m s u p p orte d at heart le vel. 
•  Be gi n t he meas ure me nt after at lea st [ADDRESS_143752]. 
•  To e ns ure a n acc urate meas ure me nt, use a n a p pr o priatel y size d c uff. T he c uff bla d der s h o ul d 
e ncircle at least 8 0 % of t he ar m. Ma n y a d ults nee d a lar ge  c uff. 
•  Ta ke t w o ( 2) s yst olic/ diast olic press ure a n d heart rate meas ure me nts se parat e d b y at least [ADDRESS_143753]’s s o urce d oc u me nt. 
•  If t he t w o press ure meas ure me nts differ b y 5 m m H g or less, t he n t he a vera ge of t he t w o 
bec o mes t he rec or de d press ure. F or e xa m ple, if t he t w o meas ure me nts are 1 2 0/ 9 0 a n d 
1 2 5/ 9 5, t he n 1 2 2. 5/ [ADDRESS_143754] olic/ diast olic press ure.  
R B M -[ADDRESS_143755] a bl e S ol uti o n 
 Pr ot oc ol R B M -0 0 7 -0 0 3   
7 0  of  7 4   •  If  t he  t w o  press ure  meas ure me nts  differ  b y  m ore  t ha n  5  m m H g,  t he n  a  t hir d  rea di n g  
meas ure me nt is ma de, a n d t he a vera ge of t he t hree bec o mes t he rec or de d press ure. F or 
e xa m ple, if t he t hree meas ure me nts are 1 1 5/ 9 0, 1 2 4/ 9 6, a n d 1 2 0/ 9 2, t he n 1 1 9. 7/ [ADDRESS_143756] olic/ diast olic press ure. T he rec or de d bl o o d press ure will be t he a vera ge of t he meas ure me nts.  
•  Rec or d  t he  heart  rate.  F or  heart  rate,  t he  a vera ge  of  t he  t w o  ( or  t hree,  if  perf or me d) 
meas ure me nts o btai ne d bec o mes t he rec or de d heart  rate. 
 
[ADDRESS_143757] will be c o n d ucte d bef ore I V T i njecti o n at Vi sit 1 ( B a s eli n e ( D a y 1))  a n d 
Visit [ADDRESS_143758] me n o pa usal (at least [ADDRESS_143759] me nses occ urre d),  has ha d her uter us a n d/ or b ot h o varies re m o ve d, or has ha d a bilateral t u bal li gati o n. To o btai n t he pre g na nc y test, 
t he s u bject s h o ul d f oll o w i nstr ucti o ns pr o vi de d b y t he ma n ufact urer of t he uri ne pre g na nc y test 
kit.
 
 
[ADDRESS_143760] I V T i njecti o n of Resc ue treat me nt.  T he c o nj u ncti va, c or nea, a n d le ns will be o bser ve d wit h t he slit -la m p bea m a p pr o xi matel y 0. 3 m m i n wi dt h a n d 1. 0 m m i n le n gt h. C o nj u ncti va, Sclera a n d C or nea will be descri be d  as n or mal / a b n or mal  wit h n otes 
if a b n or mal. 
  
L e n s L e n s   
T h e l e n s will b e n ot e d a s  n or m al/ a b n or m al, p h a kic, a p h a kic, or p s e u d o p h a kic. P h a kic l e n s 
will b e gr a d e d f or c at ar act a s n ucl e ar, p o st eri or s u bc a p s ul ar, a n d c ortic al a s d e scri b e d 
b el o w:  
N o n e  ( 0) = N o l e n s di sc ol or ati o n n or o p acific ati o n  
Mil d  ( 1) = Yell o w l e n s di sc ol or ati o n or s m all l e n s o p acit y ( a xial or p eri p h er al) 
M o d er at e  ( 2) = A m b er l e n s di sc ol or ati o n or m e di u m l e n s o p acit y ( a xi al or p eri p h er al) S e v er e  ( 3) = Br u n e sc e nt l e n s di sc ol or ati o n or c o m pl et e l e n s o p acific ati o n ( n o r e d r efl e x) 
R B M -[ADDRESS_143761] a bl e S ol uti o n 
 Pr ot oc ol R B M -0 0 7 -0 0 3   
7 1  of  7 4   A nteri or c ha m ber cells a n d flare will be o bser ve d wit h a 1. 0 m m i n wi dt h a n d 1. 0 m m i n le n gt h 
slit  bea m  a n d  gra de d  usi n g  t he  Sta n dar dizati o n  of  U veitis  N o me nclat ure  ( S U N)  scale  (S u n  Wor ki n g, 2 0 0 5 ). T he iris a n d t he p u pil will be e val uate d f or t he prese nce of cli nicall y si g nifica nt a b n or malities.  
 
A nt eri or C h a m b er C ell sA nt eri or C h a m b er C ell s   
( 0) = N o c ell s  
( 0. 5) = 1- 5 c ells 
( 1) = 6-1 5  c ell s 
( 2) = 1 6-2 5  c ell s 
( 3) = 2 6-5 0  c ell s 
( 4) = > 5 0 c ell s 
 
A nt eri or C h a m b er Fl ar eA nt eri or C h a m b er Fl ar e  
( 0) = N o n e  
( 1) = F ai n  
( 2) = M o d er at e (iri s/l e n s d et ail s cl e ar) 
( 3) = M ar k e d (iri s/l e n s d et ail s h a z y) 
( 4) = I nt e n s e (fi bri n/ pl a stic a q u e o u s) 
 
Iri s Iri s 
T he iris will be e val uate d f or t he prese nce of a n y cli nicall y si g nifica nt a b n or malities, a n d 
gra de d as eit her n or mal ( wit hi n n or mal li mits) or a b n or mal (cli nicall y si g nifica nt a b n or malit y 
prese nt). A descri pti o n of a n y cli nicall y si g nifica nt a b n or malities will be n ote d.  
 
P u pil P u pil  
T he p u pil will be e val uate d f or t he prese nce of a n y cli nicall y si g nifica nt a b n or malities, a n d gra de d as eit her n or mal ( wit hi n n or mal li mits) or a b n or mal (cli nicall y si g nifica nt a b n or malit y prese nt). A descri pti o n of a n y cli nicall y si g nifica nt a b n or malities will be n ote d.  
 
[ADDRESS_143762] a bl e S ol uti o n 
 Pr ot oc ol R B M -0 0 7 -0 0 3   
7 2  of  7 4   F or R e sc u e I V T i nj ecti o n, I O P will b e m e a s ur e d a s f oll o w s:  
- I O P will b e m e a s ur e d at 3 0 (± 1 0) mi n ut e s p o st -i nj ecti o n. 
- If p o st-i nj ecti o n I O P i s > 2 1 m m H g aft er e y e m a s s a g e a n d/ or a q u e o u s t a p p erf or m e d p er 
i n v e sti g at or di scr eti o n, I O P m e a s ur e m e nt will b e r e p e at e d at 6 0 (± 1 0) mi n ut e s p o st -
i nj ecti o n.  
- If p o st-i nj ecti o n I O P at 6 0 (± 1 0) mi n ut e s i s > 2 1 m m H g aft er e y e m a s s a g e a n d/ or a q u e o u s t a p p erf or m e d p er i n v e sti g at or di scr eti o n, I O P m e a s ur e m e nt will b e r e p e at e d at 9 0 ( ± 1 0) mi n ut e s p o st -i nj ecti o n.  
- If t h er e i s a n i ncr e a s e of ≥  1 0 m m H g at 9 0 ( ± 1 0) mi n ut e s p o st -i nj ecti o n c o m p ar e d t o pr e-
i nj ecti o n I O P , t h e s u bj ect s h o ul d b e pr e scri b e d a t o pic al I O P -l o w eri n g m e dic ati o n u ntil h e 
or s h e r et ur n s f or f oll o w -u p p er t h e Cli nic al I n v e sti g at or ’s di scr eti o n ( a n u n sc h e d ul e d vi sit 
m a y a p pl y).  
- O n t h e ot h er h a n d, a s u bj ect wit h I O P m e a s ur e m e nt of > 2 1 m m H g will b e m a n a g e d acc or d i n g t o t h e di scr eti o n of t h e Cli nic al I n v e sti g at or. 
- T h e I O P i ncr e a s e of ≥  1 0 m m H g fr o m pr e -i nj ecti o n A N D I O P m e a s ur e m e nt of > 2 1 m m H g will b e r e p ort e d a s a n A E.  
 
• A q u e o u s t a p c a n b e p erf or m e d at a n y ti m e p er t h e Cli nic al I n v e sti g at or` s di scr eti o n f or 
tr e at m e nt or pr e v e nti o n of i ncr e a si n g i n t h e I O P . 
 
T he a p pla nati o n t o n o meter m ust be cali brate d f or acc urac y bef ore t he first s u bject u n der g oes 
scree ni n g, a n d peri o dicall y u ntil t he last s u bject has e xite d t he st u d y. F or c hec ki n g cali brati o n, f oll o w t he ma n ufact urer’s i nstr ucti o ns.  
T he f oll o wi n g I O P meas ure me nt pr oce d ure is i n acc or da nce wit h t he pr oce d ure use d i n t he Oc ular 
H y perte nsi o n Treat me nt St u d y (G or d o n et al., 2 0 0 1 ) at eac h visit: 
At least t w o, a n d s o meti mes t hree, c o nsec uti ve meas ure me nts are ma de t o o btai n a deter mi nati o n 
of  i ntra oc ular  press ure.  Eac h  I O P  meas ure me nt  s h o ul d  be  rec or de d  i n  t he  s u bject’s  s o urce  d oc u me nt a n d i n t he e C R Fs. 
  
• If t he t w o meas ure me nts differ b y 2 m m H g or less, t he n t he a vera ge of t he t w o 
meas ure me nts bec o mes t he rec or de d I O P. F or e xa m ple, if t he t w o meas ure me nts  are 2 2 a n d 
2 3, t he n 2 2. 5 is t he fi nal rec or de d I O P. 
• H o we ver, if t he t w o meas ure me nts differ b y 3 m m H g or m ore, t he n a t hir d meas ure me nt is 
ma de, a n d t he me dia n of t he t hree meas ure me nts bec o mes t he rec or de d I O P (t he me dia n is t he mi d dle meas ure me nt after arra yi n g t he meas ure me nts fr o m l o w t o hi g h).    F or e xa m ple, if t he t hree meas ure me nts are 1 5, 1 9, a n d 1 6, t he n 1 6 is t he fi nal rec or de d I O P. 
• T he I O P i n t he left e ye is t he n meas ure d usi n g t he sa me  tec h ni q ue. 
R B M -[ADDRESS_143763] I V T i njecti o n of Resc ue treat me nt.  
 
C u p/ Disc R ati o  
T he c u p/ disc rati o will be deter mi ne d b y t he e xa mi ner a n d rec or de d usi n g t w o deci mal places (e. g., 0. 8 0).  
Reti n a, M ac ul a a n d C h or oi d
 
T he reti na, mac ula a n d c h or oi d will be e val uate d f or t he prese nce of a n y cli nicall y si g nifica nt 
a b n or malities,  a n d  gra de d  as  eit her  n or mal  ( wit hi n  n or mal  li mits)  or  a b n or mal  (cli nicall y  si g nifica nt a b n or malit y prese nt). A descri pti o n of a n y a b n or malities will be n ote d.  
Vitre o us
 
T he f oll o wi n g Nati o nal E ye I nstit ute Gra di n g Sc he me will be use d t o meas ure vitre o us haze a n d 
o pacificati o n (N usse n blatt et al., 1 9 8 5 ).  
Vitre o us H aze Sc ale
 
St e p St e p   D e scri pti o n D e scri pti o n   
( 0) Cl e ar  
( Tr ac e or 0. 5 +)  Tr ac e  
( 1 +) F e w o p aciti e s, mil d  bl urri n g  
( 2 +) Si g nific a nt bl urri n g b ut still  vi si bl e  
( 3 +) O ptic n er v e vi si bl e, n o v e s s el s  s e e n  
( 4 +) D e n s e o p acit y o b sc ur e s t h e o ptic n er v e  h e a d  
 
[ADDRESS_143764] u d y Visit 1 ( Baseli ne  Da y 1 ) a n d Visit 
5 ( M o nt h 4) i n all s u bjects. T he i ma ges ma y be st ore d i n t he E g n yte ser ver . 
R B M -[ADDRESS_143765] ore d i n 
t he E g n yte ser ver a n d se nt t o t he ce ntral rea di n g ce nter at a later date at S p o ns or discreti o n. 
2 1. 4. 1 3 F u n d us A ut of l u orescence    
F u n d us a ut ofl u oresce nce will be perf or me d  at Visit 1 (Baseli ne ( Da y 1) ) a n d Visit 5 ( M o nt h 4). 
T he i ma ges ma y be st ore d in t he E g n yte ser ver  a n d se nt t o t he ce ntral rea di n g ce nter at a later date at S p o ns or discreti o n. 